Sham-operated animals
policy





treatment

Heart failure ; uk
CHF
air pollution ; heart failure
voordelen ; exercise ; cardiovascular system


HF
eh


diuretic ; heart failure


follow-up
Cell ; Anand
doxorubicin
blood transfusions
Heart failure ; bisphosphonates
cox proportional hazards
Caspase-3 gene expression ; heart failure
right heart failure ; pulmonary hypertension

exercise ; cardiovascular health
cute care surgery ; heart transplant recipients

Renal artery stenosis

HF ; pNA
molecular mechanism
tertiary referral centre
ec


dXA
FM
devices ; heart failure




heart failure ; Latin America
HF


breathing ; heart beat

Heart rate



Nutrition ; heart failure
northwest United States



heart failure
INTERvenTIONS

Heart

clin

trans


interne ; Cronbach
hypertension


cox regression analysis
implanted monitoring devices


HR ; Ea
strokes
frailty ; heart failure

exercise ; heart failure
RAS ; atherosclerosis
microRNAs ; heart failure ; disease management
psss
management ; heart failure ; ejection fraction
Cardiology ; bromodomain inhibition ; heart failure

heart failure ; hospitalization ; cardiovascular death
cognitive function
co ; mixed linear models
vasopressin ; congestive heart failure
mitral stenosis ; medical ; heart failure
cardiac transplantation
inpatient medical conditions
HF

LV fibrosis ;ANS mice

dodson

CHF
heart failure
intermediate frailty
competitive

autonomic balance
HFpEF
Jehovah ; witness ; anemia
ST2
Heart failure ; cognitive impairment ; mortaliteit
cardiology ; university hospital
follow-up
current ;HF ; HF

hemostasis

Heart failure ; disease
HF ; MI

Remote ischemic conditioning ; heart failure
Heart rate ; cardiac patients
cardiovascular disease
arrhythmia-related kosten

pde2 ;HF
mortaliteit ; sts HM


Heart failure ; public health problem
albumin level
median follow-up

follow-up
HF
hospital
ET ; CHF
eRK ; molecular scaffolds ; heart pathology
spironolactone ; systolic heart failure
cox proportional hazards
Heart failure ;HF ; mortaliteit ; society
chronic heart failure ; bisoprolol
functional MS ; degenerative MR

lVET ; aortic pressure curve
Cardiac symptoms ; children
Devices ; heart failure ;HF ; therapy
Trastuzumab-related cardiotoxiciteit ; breast cancer
physician continuiteit ; discharge

Tolvaptan ; vasopressin ; receptor
metric ; readmission metrics

propensiteit

black
MR ; MS ; functional
Cardiac amyloidosis
ejection fraction ; bNP
HFpEF
beta blockade
significant
Robot-assisted training ; heart failure patients
functional capacity
Chronic HF
follow-up
Pigs ; antiarrhythmic medication
Heart rate ; arterial pressure
hgb level ; HRQoL
ejection fraction outcomes trial
mortaliteit
cardiac ; inflammatory biomarkers
HF ; cardiovascular hospitalization
CHF ; intubated
circulatory arrest
biomarkers ; chronic heart failure
heart failure ; emergency department
systolic dysfunction
HF
north America
acute heart failure trials

therapy
AHA ; ESC
cPGs

MS ; surgery
systemic blood pressure
patients ; heart failure
stand-alone diagnostic devices ;HF
end stage heart failure
HF

significant
sepsis
Nordic walking ; heart failure
Psychometric testing ; Self-care of Heart Failure index
heart failure scans
acute kidney injury
cox proportional hazards

heart failure ; cox proportional hazard analyses
MS ; surgery ; echocardiography
Pharmacological ; acute heart failure ; treatment
voordelen
abnormal cardiac t2 ; treatment

heart failure
healthcare programmes
biomarkers
AIN oUTCOME ; tug test



drug ; japan

VO2max

Coronary angiography
dialysis ; device implantation
off-pump ; sternal sparing ; HeartMate i exchange
Hemodynamic phenotype ; Fontan
ESRD
Seattle Heart Failure model

HR ;HF
Heart failure ; left ventricular ejection fraction
AI ; surgical
acute heart failure
significant
algorithms ; post- lVAD AI


voordelen ; anemia treatment ; heart disease

QRs ; benefit

Rhythm- ; rate-control
follow-up
Public reporting ; hospitals
sinus rhythm ; AF
diagnostic ; filling pressures
care management ; telehealth ; medicare

deficit index
HF
heart failure ; cardiac rehabilitation
Race ; spironolactone ; heart failure
Myocardial infarction ; Wistar rats

molecular level ;HF ; chromatin hyperacetylation
mortaliteit
gLS ; CV ; AF
MS ; surgery

medication ; hemodynamics


systolic HF
postsystolic function
lVAD implantation
hospital ; heart failure ; discharge
gross income ; expenditure ; health

aac ; cardiac hypertrophy
heart failure
keletal muscle ; exercise capacity ; Fontan circulation
progressive ; hypertension ; kidney failure
chronic kidney disease ;CKd
hospital
anaerobic threshold ; heart failure
ral regurgitation ; HF ; surgery
CHF ; unilateral renal DNx ; cardiac autonomic balance
renin-angiotensin-aldosterone system inhibitors ; heart failure
abnormal HR variabiliteit ; cardiac death
inflammation ; metabolism ; heart disease
Heart block ; pulmonary artery ; BiVP
congenital heart lesions
functional MS
AF ; echocardiographic examination
bioinformatic ; microarray ; genes ; heart failure
follow-up ; cardiovascular events ; deaths
diuretic ;HF
CAD ; systolic HF
pvf ; pb
Nurses ; patients
diabetes ; eEO-cFUs ; functional capacity
blacks ; VO2
odds ratios ; accounting ; hospital clustering
lVET ; follow-up measurement
nitroxyl ; hno ; acute treatment ; heart failure
physician ; death ; urgent readmission ; discharge ; heart failure
hFrEF ; HFpEF
Care packages
hospital-to-Home ; hospital ; readmission reduction ; congestive heart failure
economische ; kosten
HF
cRT ; dialysis-dependent patients
significant ; MS ;HF ; surgical indication ; MS

ICU mortaliteit
Cardiac function ; pressure-volume conductance catheter system
RM
beta-blockers
CHF
sst2 ; benefit ; BB therapy
idiopathic dilated cardiomyopathy
Hypoalbuminemia ; heart failure
hypertensive LV dysfunction ; MR ; significant MS
HF ; etiologies
angiotensin receptor ; neprilysin inhibitor ; heart failure
Western blot analysis ; immunohistochemistry ; electron microscopy
diastolic dysfunction ; peripheral artery disease
unfolded protein response ; cardiac sodium current ; systolic human heart failure
cardiomyopathy ; male sex ; mortaliteit
Exercise intolerance ; chronic heart failure
deficit index ; biological phenotype ; mortaliteit
exercise training ;ET ; endothelial function
CV ; death ; non-fatal stroke ; hospitalisation ; heart failure
AVd ; VVD ; free wall ; RS
Fat ; cachexia ; right ventricle ; heart failure
Atrial fibrillation ;AF ; heart failure
ect ; advanced heart failure therapy
heart transplantation ; left ventricular assist device
coronary disease ; heart failure
complications ; dialysis patients
right ventricular function ; body composition ; advanced heart failure
eCGs ; electrocardiographers
left ventricular assist device ; right ventricular support
ESRD ; outpatients ;HF
Wilcoxon
atherosclerosis ; linear
resistin levels ; heart failure
fm ; FM ; body weight ; CC
Renal artery stenosis ;RAS ; peripheral arterial disease
neurological ; cardiovascular events
signalling pathways ; cardiac remodelling
proteome ; HDl particles ; shotgun ; lc-MS ;MS
heart rate variation
social ; exercise ; exercise time
rehospitalization
Cardiac cachexia ;cc ; body composition
MS ; significant ; mVA
proteins ;TAC
Mediterranean ; DASh ; diet scores
heart failure guidelines ; nurse leaders
HF
southeastern Minnesota ; HF
left ; branch block ; electrical activation sequence
hHF ; dPP-4 inhibitors ; drugs
AF ; hbf
heart transplant ; ect
cRF
death ; heart failure clinic ; outpatients
Cardiac-resynchronization therapy ; heart failure ; QRs complex
medications ; adults ; heart failure
miRNAs ; cardiac pathogenesis
heart failure ; care
bt ; dt
mortaliteit
coronary heart disease ; stroke ; heart failure
significant ; MLHF Questionnaire
surgical intervention
mortaliteit ; iCD-HF patients
follow-up ;HF
hypotension
mortaliteit
Î²-blocker ;bb ; sST2
discharge ; follow-up medication

extubated ; blood loss ; transfusion requirements
techniek ; HeartMate ii ; lVADs
Heart failure ;HF ; cardiovascular hospitalization
ST2 ; plasma samples
VEGF inhibition ; cardiac function ; remodeling
biomarkers ;HF
trastuzumab-related CHF
Health ; aerobic exercise
hospitals

transplants ; died

VO2
hospitals

bromodomain proteins
significant ; economische
financiers
hypoalbuminemia ; lVAD surgery
holosystolic murmur ; heart
psoriasis ; atherosclerosis ; cardiovascular events ; Rotterdam Study
Coronary artery disease ;CAD ; systolic heart failure ;HF
mortaliteit ;HF ; hospital admissions ; transplant ; ventricular assist device
Heart failure ; rheumatoid arthritis ; tNF antagonist
HF ; haemodynamic ; neuronal stressors
lVAD implantation
renal dysfunction ; post-transplant morbiditeit
germline DNA ; genotyped
Heart failure ; disease management ; medical resource
Renal DNx ; circulating plasma ; rabbits
treatment
trastuzumab
NP assessment ; ED patients
Cardiac hypertrophy ; energy metabolism
HF
blood work ; medication
heart failure
Heart t2 ; heart failure ; arrhythmias
activated Caspase ; myocardium
heart failure ; older adults ; body composition
hHF ; saxagliptin ; sitagliptin
follow-up ; HF
acr ; CMS
HDL-bound malondialdehyde ; ec
ED ; intubations ; congestive heart failure
derivation cohort ; CAD ; CAD


hospital discharge

voordelen ; anemia ; adults ; heart disease
heart failure ; diagnose ; medication ; follow-up
regulatory subunit ;RI ;HF
heart failure ; ejection fraction
cPET ; guiding exercise rehabilitation ; CHF
nfat ; mir-25 ; transcription factor ; hand2 ; heart failure
Pediatric heart failure ;HF
eplerenone
renal denervation ; autonomic balance ; rabbits ; chronic heart failure
readmissions ; follow-up visits ; heart failure ; readmission quality
resistin ; ejection fraction
Right atrial myxoma ; pulmonary embolism ; right heart failure
Orthotopic heart transplantation ; owt ; treatment ; heart failure
Myxomas ; right atrium ; pulmonary arterial vasculature
ect ; cardiac transplant recipients
deficit index ;SD
Diet score ; vegetables ; nuts ; whole grain intake ; mortaliteit
benefit

iron
ED ; CHF
right ventricular contractile reserve ; pulmonary hypertension
Gastrointestinal bleeding ; ventricular assist devices ; cardiac nurse
Soluble ST2 ; ambulatory patients ; heart failure ; functional capacity
echocardiograms
Titin hypophosphorylation ; myocardial DD
remote monitoring ; hospital discharge ; heart failure
bottleneck stent ; chronic myocardial ischemia ; heart failure ; pigs
QT intervals ; SD ; QT intervals ;SDt
LV ; filling pressure ; severe systolic HF
medLine ;EMBAse ; cINAHL
benefit ; Î²-blocker uptitration ; HFpEF
c pcs ; functional capacity ; VO2
pump ; driveline injury ; isolated pump replacement
ischemic ; inflammatory abdominal problems ; MT
eh ; HFpEF
Framingham Heart Study ;HF ; EF
Nicorandil ; orally ; doxorubicin treatment
fes
guideline ; aCP
diuretics ; congestive symptoms ; heart failure ;HF
chronic heart failure ; tachycardia
lVAS ; transplantation
Cardiac ; Mammalian enabled ;Mena ; heart failure
east ; rhythm control therapy ; cardiovascular complications ; AF
HF
coronary artery disease ;CAD
noc
HRQol ; exercise training ; baseline hgb
skeletal muscle mass ; VO2
atrial fibrillation ; pacemaker
inpatient records ;HF
active treatment ; placebo
cardiac resynchronization therapy ; dialysis-dependent patients ; heart failure
pneumonia ; surgical conditions
diastolic failure ; cardiomyopathic restriction ; flow
injections
pump exchanges ; pump malfunctions ; pump thrombosis ; hemolysis events
cardiac catheterization ; extubated
psychosocial factors ; exercise training ; heart failure ;HF
heart failure ; children ; Canadian Cardiovascular Society ; guidelines
ees ; ventricular-arterial coupling ; SV
benefit ; QRs
autonomic nervous system activity ; ncw
device implantation ; cRT
aRIC HF


degs ; osprey
therapy
world health Organization ; HF ; LA
Medicare ; post-acute care transfer policy
cardiovascular reason
paediatric cardiac transplants
catheter ablation ; sinus rhythm
body mass index ; cRF ; treadmill ; exercise testing
myocardial tissue ; pka subunits
mortaliteit ; iCD-HF
t1 mapping ; significant ; myocardial fibrosis

Medicare ; hospitalizations

white
SD ; diet adherence ;SD

thics Rounds

therapeutic ; heart failure
ED ; CHF ; intubation rates
bisoprolol ; mortaliteit
Health Buddy Program ; telehealth system ; care management
muscle-wasting syndrome ; acquired heart failure ; Fontan

heart rate reduction ; ivabradine unloads ; left ventricle ; heart failure
vrvPO ; BiVP ; RS synchrony ; CS
anemia ; heart disease ;American college of Physicians
cardiovascular death ;HF ; exercise training ; btes
regelmatig ; heart failure ; lipoprotein functional properties
Heart rate ; aortic blood flow ; doxorubicin

Myocardial pde2 ; HF
resistin ; acute anthracycline-induced cardiotoxiciteit
acute autonomic nervous system modulation ; Qt ; HF
BAT ; sympathetic outflow ; parasympathetic activity
renal disease ; outpatients ; systolic heart failure
Neurohormonal abnormalities ; pathophysiology ; congestive heart failure ; chw
echocardiographic ; reverse remodeling ; cardiac resynchronization therapy
parasympathetic neurotransmission ; acetylcholinesterase inhibition
renal DNx ; cardiac autonomic balance ; CHF ; sympathetic tone
Heart Failure ; Pathophysiology ; Medical Treatment Guidelines ; Nursing management
biomarkers ; neurohormonal stimulation ; inflammation ; endothelial dysfunction
Canada
myocardial washout
right ventricle ; vn ; cardiac function
kosten ; heart failure ;HF
HF
mortaliteit ; bNP ; mortaliteit
cardiopulmonary exercise ; heart failure
rv dysfunction ; weight loss ; fat ;lean body mass ratio
chromatin subproteome ; mouse heart
HR ; beta blockers ; exercise capacity ; hFrEF
protein kinase ; soluble guanylate cyclase ; contractile response
student t test ; confidence intervals ;CIs ; regression analyses
c pcs ; functional capacity ; heart failure ;HF
morbiditeit ; mortaliteit ;HF
corruptie ; aCS
psss ; social support ; btes
ctnt ; NT-probNP ; significant ; HF
Jehovah's Witness ; sickle cell disease ; anemia
miRNAs ; therapeutic targets ; heart failure
physician continuiteit ; hospital discharge
tent inhibition ; l-type ca2+ currents ; Rad variant ; congestive heart failure
congestive heart failure ; ncw
Health Buddy Program ; ED ; hospital days
mRI scanner ; heart failure
cardiac stress ; Î²-AR drive
left pulmonary artery ; right pulmonary artery
dobutamine ; furosemide dose ; oxygen flow
LVEF ; mortaliteit
Mediterranean ; DASh ; diet scores ; mortaliteit ; women ; heart failure ; Women's Health Initiative
c pcs ; diabetes
anthracycline-treated breast cancer ; cardiotoxiciteit
death ; transplantation ; circulatory assist device
Nursing-sensitive outcome change scores ; older adults ; heart failure
devices ; diagnostic features ; fluid overload

transcatheter ; surgery
resistin ; chemotherapy-induced heart failure ; breast cancer
insurance status
black race ; mortaliteit
chelation regimens ; heart iron
Time Up ; Go test ; chronic organ failure
death ; heart failure
ST2 level ;interquartile range
pressure ulcers ; surgical patients
HF ; valve plasty ; MS ; significant ; mVA
PD ; refractory ; end-stage congestive heart failure ; chw
wha ; functional assessment
beta blockers ; mortaliteit ; heart failure
MT ; abdominal problems
follow-up visits
mortaliteit
futility ; safety monitoring board
diagnoses ; treatments
Stress ; doppler echocardiography ; pulmonary hypertension
ejection fraction ; cardiac resynchronization therapy ; mild heart failure
co ; septal wall ; vd ; free wall ; CS ; vn
strain ; strain rate ; echocardiography ; baseline ; ablation
circulating progenitor cells ; heart failure patients
etiologic ; acute RV failure ; left ventricular dysfunction
systolic ; diastolic mitral leaflet ; motions
myocardial diastolic dysfunction ; dd ; collagen deposition
ventricular ejection time ; acute heart failure ; precapillary pulmonary hypertension
aortic valve insufficiency ; left ventricular assist device ; implantation
biventricular pacing ; left heart ; twist ; strain ; porcine model ; right heart failure
cardiac nurses

UM ; va-RT
heart failure
health ; benefits
Czech Republic
investering ; cardiac catheterization ; thrombotic obstruction ; right coronary artery
Western blots ; monoclonal antibodies ; Ser83 phosphorylation ;HF
hbf ; sodium restriction ; ventricular ; vascular
echocardiographic ; invasive hemodynamic
chronic heart failure ; chw ; sympathetic tone ; autonomic imbalance
california ; office of Statewide healthplanning and development ; Patient Discharge
right atrium mass ; tricuspid valve ; stenotic physiology
serum albumin ; left ventricular assist device ; implantation
functional capacity ; mwt
older adults ; HF
CHF ; atrial explants ; sham explants
Chinese herbal medicine ; dilated cardiomyopathy ; heart failure
implantable ; cardioverter-defibrillator deactivation

economische ; AF ; heart failure ; QuÃ©bec ; Canada
cardiac Mena deletion ; cardiac dysfunction ; conduction abnormalities ; hypertrophy
electromechanical delay ; dyssynchronous heart failure ; computational study
trastuzumab ; cardiac comorbidities
bundle-branch block ; lbb ; non-LBbb
Font failure ; systolic ventricular function ; significant liver disease
eh ; CH ; cardiac filling pressures
protein levels ; Western blot ; DNA fragmentation ; tunel method ; autopsy samples
extracorporeal membrane ; oxygenation ; bridge ; infarction-related refractory right heart failure
dilated cardiomyopathy
Heart failure ; mortaliteit ; Western society ; cardiovascular diseases
magnetically Levitated left ventricular Assist system ; Treating Advanced HF
anticoagulation ; therapy ; heart disease ; rate control
inotropic effect ; beta blockers ; heart failure
PAD ; ankle-brachial index
HR ; ivabradine ; TAC ; Ea
NT-probNP ; circulation ; HF
energy metabolism ; heart failure ; hypertrophied heart
cancers ; budget
mechanical cardiac support ; renal function
systolic function ; therapeutic
ecmo ; VAD ; ecmo+VAD
psoriasisasis ; smoked ; diastolic blood pressure ; body mass index
HRQol ; linear
ED physicians ; New Jersey ; New York
cox ; ST2 ; functional capacity
MS ; functional ; MS
transfusion thresholds ; mortaliteit rates
TM ; sts
HF
Seattle Heart Failure
MADt-cRT ; device
neurological ; cardiovascular
bets ; mouse TAC ; human HF
nitrite
aHF

no ; flow-mediated dilatation ; ET
dopamine ; nesiritide
cutoff level
heart failure ; protein kinase
cox regression ; cardiovascular events ; psoriasis
cp ;HF
Paco2 ; cerebral blood flow ; perfusion ; carotid bodies
functional MS ; medical ; treatment ; surgical
HF ; health service provision ; HF ; LA
heart failure ;HF
renal dysfunction ; mechanical cardiac support
Heart failure ;HF ; chronic disease
ventricular assist devices ; device therapies
hemoglobin levels
exploratory factor analysis ; cFA

heart failure ; systolic heart failure
rhythm-control ; rate-control
follow-up ;cf lVAD ; AI ; heart failure
anemia ; heart disease
left ventricular dilatation
serum factors ; coagulability
device ; implanted ; follow-up
pb ; HF
iCD

HF
computing readmissions ; hospital rankings
echocardiography ; shunt implantation
pro-adrenomedullin ;MR-proadm ; fm
New York Heart association ; walk test ; quality-of-life
functional ; MS ; ring annuloplasty ; ischemic MR ; LV dilatation
Exercise intolerance ; heart failure ; exercise parameters
pathophysiology ;HF ; medical management
ventricular assist device ; extracorporeal membrane oxygenation ; renal function ; heart failure
interleukin receptor family ; ST2 ; beta-blocker therapy ; chronic heart failure
bNP ; NT-probNP ; biomarkers ; heart failure
Cardiorespiratory fitness ; body mass index ; heart failure mortaliteit ; Cooper Center Longitudinal Study
vasopressin receptor antagonist ; tolvaptan ; Japanese heart failure patients
diet ; exercise ; attention control ; telephone

acute HF
administration ; trastuzumab-related CHF

cardiac death

hospital mortaliteit
medical records
ejection fraction ;EF ; infarct ; collateral growth ; myocardial perfusion
Heart failure ;HF ; sympathetic activity ; parasympathetic control ; heart
physical activity ; cardiovascular risk factors ; obesiteit ; diabetes mellitus ; hypertension ; hyperlipidaemia
circulating fragments ; natriuretic peptides ; plasma ; heart failure patients
heart failure ;HF ; left ventricular ejection fraction ;HFpEF
rial fibrillation ; congestive heart failure ; cost ; rhythm-control ; rate-control
HF ; cardiac murmurs ; blood pressure ; hg
ATP demand ; XO-mediated ROS ; mitochondrial respiration ; contractile function
b ; cardiac angiogenesis ; in vivo coronary perfusion ; cardiac fibrosis
heart failure ; prone ; ventricular tachycardia
tug test ; COPd ; CHF ; cRF
pressure-overload-induced heart failure
Nursing ; social mandate ; nursing care
HF ; vt ; beat-to-beat QT intervals
biventricular dysfunction ; isolated HeartMate ii
economische ; hemodynamically unstable ; cPR
heart failure ; implantation ; ventricular assist device
Pyridostigmine ; myocyte diameter ; collagen density ; left ventricle
isoproterenol ; cXL-1020 ; myocytes ; hearts
Exercise intolerance ; chronic hFPEF ; ncw
receptors ; adenylyl cyclase ; g-protein coupling
systolic HF ; unclear etiology ; coronary angiography
mortaliteit ; implantable cardiac defibrillator
jugular venous pressure ; peripheral oedema ; volume
Heart failure ;HF ; condition ; significant
CAD ; systolic HF
pump-exchange techniek ; sternotomy ; cardiopulmonary
chirurgische revascularization ; catheter-based revascularization
Base hgb ; exercise ; ncw
HF ; HF ; MS ; mva
MS ; medical treatment ;HF ; functional ; MS ; medical treatment

parasympathetic function ; therapeutic ; wh
race ; exercise ; ambulatory HF
mechanical cardiac support ; renal function ; children ; end-stage heart failure
CH ; eh ; systolic blood pressure ; renal impairment ; hypertension
chronic myocardial ischemia ; heart failure
Morpholino-based knockdown ; nucleolin ; protein expression
rehospitalization
HFpEF
CAD ; CAD
diabetes mellitus ; cardiovascular disease
cachexia ; rv function ; body composition

ecmo group ; egFR ; egFR
haemodynamic ; pulmonary ; peripheral abnormalities
hospital ; cardiac specialty hospital ; South dakota
cognitive impairment
acs ; MT ; VAD
CVd ; psoriasis
energy substrate metabolism ; isolated working hearts ; aac
schei
Rotterdam ; psoriasis ; cardiovascular outcomes
HR ; ncw ; nbDMARD
Spironolactone ; hyperkalemia ; kidney injury
heart ; nontraumatic death
Fontan circulation ; skeletal muscle mass ; metabolic abnormalities

cardiovascular conditions ;HF
isolated HeartMate i lVAD
albumin levels ; lVAD
mineralocorticoid receptor antagonists ; race
right heart circulation ; right heart failure
MI ; MI ; HF
Fontan circulation ; sVR index ; cardiac index
isolated lVAD ; patients
health insurance ; health system ; u.s. Food and Drug Administration
cutoff value ; NT-probNP testing ; ED ; acute heart failure
blacks ; hypertension ; diabetes ; ischemic etiology ; socioeconomic status ; whites
bisphosphonate ; heart failure
Cytoscape ; functional enrichment analysis ; daVID
Raf-MEK1/2-ERk1/2
kosten
sustainability

patient safety
EMd
mouse ;HF ; compensated LV hypertrophy ; HF ; hHD
heart failure ; preserved ejection fraction ; doppler echocardiography
natriuretic peptide ; biomarkers ;POc
anticoagulants ; antiplatelet drugs ; heart failure ; atrial fibrillation
sympathetic ; parasympathetic activity ; HF
left ventricular longitudinal systolic strain ; cardiovascular events ; atrial fibrillation
follow-up ; heart transplantations ;LV assist device implantations ; heart failure admissions
functional mitral stenosis ; ring annuloplasty ; ischemic mitral regurgitation
Xanthine oxidase inhibition ; ventricular systolic ; diastolic function ; cardiac volume overload
bNP ;PAD ; bNP ; HF
heart failure ;HF ; Heart Failure ; adherence ; retention trial ;HARt
HF met preserved ejection fraction ;HFpEF ; hypertension
NYha ; functional class ; quality-of-life score
Myocardial infarction ; left anterior descending ; coronary artery occlusion
HFpEF ; breathlessheid ; fatigue ; fluid retention
immunodetection ; NT-probNP ; antibodies
Nordic walking ; cardiac rehabilitation ; functional capacity ; heart failure
parasympathetic tone ; pyridostigmine ; ventricular dysfunction ; heart failure
Î²-Blockade ; cardiac angiogenesis ; heart failure ; VEGF signaling pathway
myocardial ischemic events ; cardiac resynchronization therapy
aortic valve surgery ; new-onset post- lVAD ; AI
unloading ; heart ; isolated HR reduction ; systolic heart failure
spironolactone ; adults ; systolic heart failure
Heart failure ; medicine ; atheromatous coronary disease
Heart failure ;HF ; Latin America ; lissabon ; HF
rehospitalization ; medicare ; discharged ; skilled nursing facilities
HF ; cRT ;hazard ratio
palliative ; advanced disease
diagnostic test ; HFpEF ; medical ; physical
oxidative stress ; GTPase Rac1 ; hearts ; ANS mice
circulating mediator ; insulin resistance ; monocytes ; inflammatory stimuli
cardiovascular death ; urgent cardiac transplant ; death
medications ; outpatients ; heart failure ; ncw PINNACLE program
beta-blockers ; cardiac sympathetic activity ; hemostasis ; heart failure
CHF ; emergency department ; dc ; intubated
lcx ; LAD
RV dysfunction ; weight loss ; abnormal body composition ;HF
congestive heart failure
mitochondrial structure ; sarcomeric microstructure
heart failure ; Emergency Department ;ED ; ED
non-ischemic ; ischemic heart failure
pp ; acr ; CMS
gut ; inflammation ; dietary interventions ; heart failure ; heart failure
heart failure ; ejection fraction
Intravenous iron ; heart failure ; iron deficiency
robot-assisted gait therapy ; Lokomat ; system ; heart failure
stress conditions ; heart failure
significant
significant


psoriasis ;UV treatment
NT-probNP ;HF ; plasma ; immunoprecipitation ; mass spectrometric analysis
Chromatin-associated proteins ; chromatin structure ; DNA ; gene expression profile
diastolic dysfunction ; hFPEF
right ventricle overload ; stroke volume ; left ventricular ejection time ; lVET
Î²-Adrenergic receptor blockade ; mortaliteit ; heart failure ;HF
PD ; complications ; therapy ; HF
transoesophageal echocardiography ; shunts ; patent ; thrombosis ; migration
line ; mutant mice ; hand2 ; healthy heart muscle cells ; pathological hypertrophy
physician follow-up after discharge ; death ; readmission ; heart failure
dialysis ; echocardiographic outcomes
zSF1 rats ; heart failure ; ejection fraction
ambulatory HF ; ventricular ejection fraction
QT variabiliteit ;Qt ; Qt ; cardiac death
Cross-talk ; heart ; adipose tissue ; cachectic heart failure ; body composition
arterial tonometry ; lVET ; precapillary PH ; heart failure
heart ; magnetic resonance imaging ; chelation choices ; heart disease ; thalassaemia major
paraDIGm-HF ; paradigm shift ; chronic heart failure ; Chronic heart failure ; cardiology
abm ; implantable cardioverter-defibrillator deactivation
New Zealand ; White rabbits ; renal DNx ; CHF
ET ; HDl function ; ET ; CHF-NYha-IIIb ; HDl function
catheter ablation ; antiarrhythmic drugs ; rhythm control therapy
lVET ; death ;ICU
therapeutic ; exercise ; hemodynamic status
Cardiac failure ; diabetes ; molecular mechanism ; diabetes ; heart failure
pulmonary hypertension ;PH ; heart failure
Beta-blocker dose ; resting ; HR ; bpm
CHF ; therapeutic interruption ; activated neurohormonal systems
heart rate ; renal function ; spironolactone
microRNAs ;miRNAs ; heart failure
multiacquisition ; t1-mapping ; mRI ; tidal respiration ; myocardial t1 ; swine ; heart failure
HF
miRNAs ; cardiac remodeling ; heart failure

cardiovascular disease ; dRS ; deciles
follow-up
AMI mortaliteit rates

frailty ; risk ; heart failure ;HF ; older adults
heart failure ; bisphosphonates
beta-blocker therapy
psoriasis ; cardiovascular disease ;CVd
pde2-overexpressing ; cardiomyocytes ; norepinephrine-induced hypertrophic responses
readmissions
cardiovascular disease

POc technology
Rhythm control therapy ; benefit ; side effects
RAS-blocker uptitration ; hFrEF ; HFpEF
diastolic dysfunction ; filling pressures ; doppler echocardiography
Hemoglobin ; exercise ; chronic heart failure ; HF-acTION
cardiac dysfunction ; subcellular alterations ; metoprolol ; heart failure ; myocardial infarction
Myocardial collagen ; collagen cross-linking ; titin isoforms ; phosphorylation
Cardiac magnetic resonance postcontrast ; heart failure ; ejection fraction
systems proteomics ; cardiac chromatin ; nucleolin ; regulator ; cellular plasticiteit ; cardiomyocytes
cardiotoxiciteit ; doxorubicin ; anti-neoplastic agent ; cancers
heart failure ; left ventricular ; vn ; ejection fraction
Fontan ;SAF
natriuretic peptides
alphaLISa ; immunoassays
HF ; rheumatoid arthritis ;RA
hospital rates ;HF ; CMS
implantable ; cardioverter-defibrillator deactivation
sinus rhythm ; antiplatelet agents ; anticoagulants
death ; biological phenotype ; deficit index
Î²-Blocker-induced enhancement ; cardiac angiogenesis ; therapy ; cardiac function
index admission ; index admission
Bax ; bcl-2 proteins
GDt ;control group ; GDt ; BAT ;treatment group
heart failure ; CLcnka sNP
alendronate ; alendronate ; heart failure
transduction pathways ; proteins
HR
Plasma samples ;HF
feeding ; nutritional ; anti-inflammatory effects ; CHF
diastolic dysfunction ; mortaliteit
acs ; oHT ; transplant ; mt ;VAD
Î²-blocker dose
drugs ;HF ; ejection fraction ;HFrEF
Kansas City Cardiomyopathy Questionnaire ; heart failure ; ejection fraction
heart failure ; preserved ejection fraction ; hbf
bNP ; NT-probNP ; coronary artery disease ;CAD
functional mitral stenosis ; m ; ring annuloplasty ; ischemic mitral regurgitation ;MR
heart failure-related hospitalization ; death ; left ventricular ejection fraction
refractory congestive heart failure ; peritoneal dialysis
heart failure ; elevated left atrial pressure
lean ; zSF1 group ; hypertensive ; obese ; zSF1 groups ; hypertensive ; diabetic
tissue ; doppler imaging ; left ventricular filling pressure ; systolic heart failure
Heart failure ; preserved ejection fraction ;HFpEF ; cardiovascular morbiditeit
MT ; VAD groups ; aCS
diastolic dysfunction ; combinatie ; figuur ; hbf
Mammalian enabled ;Mena ; cytoskeletal actin dynamics ; heart failure ;HF
Gastrointestinal bleeding ; ventricular assist devices
ARNI inhibitors ;angiotensin-receptor neprilysin inhibitors
fes ; preserved ejection fraction ;HFpEF
Myxomas ; cardiac benign tumors ; left atrium
nicorandil ; cytotoxic effect ; doxorubicin ; ehrlich carcinoma
iCD ; mortaliteit
Heart failure ; preserved ejection fraction ; hbf ; cardiovascular reserve
Renal denervation ; dnx ; CHF
physician follow-up ; discharge ; physician continuiteit ; heart failure
hyperkalemia ; kidney injury ; spironolactone
activating ; myocardial pde2 ; intracellular antiadrenergic therapeutic strategy ;HF
carotid ; psoriasis
coronary occlusion ; significant ; collateral growth ; stent occlusion
follow-up ; HF
combinatie ; diet ; VO2 ;joint effect
voordelen ; spironolactone ; medications
RV dysfunction ; cardiac cachexia
eCG ; cRT
Mechanical dyssynchrony ; QRs complex ; cRT
pharmacologic treatment
IE ; heart failure ;HF ; death
chronic heart failure ; Hungary
breast cancer patients ; trastuzumb-related CHF
remote monitoring ;RM ; heart failure

NT-probNP
pvf ; pb ; pb
transfusions ; heart disease
control group ; exercise group
sst2 ; BB ; cardiovascular event rate
ect
significant ; aerobic capacity ; left-hand grip strength ; body weight ; waist circumference ; anxiety
Myocardial loss ; iRS1 ; iRS2 ; heart failure ; p38alpha MAPK ; insulin resistance
heart failure ; hypertensive heart disease ; angiotensin II infusion ; nephrectomy ; salt loading
ICU admission ; precapillary PH ; heart failure
renal dysfunction ; mortaliteit ; cardiovascular events ; primary isolated CABG
isoprenaline infusion ; SDQT ; hNorm ; HF
heart failure ; ejection fraction ; myocardial infarction
coronary artery disease ; systolic heart failure
Ea ; arterial compliance ;TAC ; end-systolic elastance ; ees
aldosterone antagonist ; heart failure
Genetic ; anthracycline-related congestive heart failure ; haematopoietic cell transplantation
cardiovascular risk factors ; diabetes mellitus ; atrial fibrillation ; coronary artery disease ; HFpEF
Renal dysfunction ; myocardial infarction ; coronary artery bypass grafting ; cab
Biventricular support ; HeartMate ii lVAD ; CentriMag rVAD
angiogenesis ; post-myocardial infarction heart ; heart failure
pde2 ; hearts ; Î²-AR stimulation
surgery ; medical ;HF ; hypertension ; vasodilators ; diuretics
egFR ; diuretics ; uncontrolled hypertension ; ESRD
heart failure ; death
Point-of-care systems ;NP ; ED ; community outpatient settings ; acute heart failure
mortaliteit ;hazard ratio
trastuzumab ; CHF ; nontrastuzumab
anemic ; iron-deficient adult ; heart disease
HR ; beta-blocker therapy
acute heart failure ; aHF ; heart failure ;HF
psoriasis ; disease ; atherosclerosis ; cardiovascular events ; psoriasis
HF ; EMd ; dyssynchronous failing heart
Pyridostigmine ; vascular endothelial growth factor ; protein ; left ventricle ; myocardial angiogenesis
idiopathic dilated cardiomyopathy cohort
cardiac ; plasticiteit ; disease ; chromatin remodeling
CHF ; international Classification of Diseases ; Ninth revision
medline ;EMBAse ; cochrane databases ; clinical trial registries
egFR ; VAD group ; ecmo ;VAD group ; ecmo
Ea ; TAC ; HR ; ees
ERC ; pure epicatechin ; muscle function
Robot-assisted gait therapy ; Lokomat ; system ; heart failure
cRF ; HF mortaliteit risk ; HF risk factors
rv dysfunction ; lower body mass index ; fat mass index ; cachexia
HF ;HF
myocardium ; displays ; pka ; downstream signaling
Care management ; content-driven telehealth technology ; health outcomes ; Medicare
hFPEF
exercise ; health benefits ; cardiac disease ; heart failure
HDl function ; CHF ; eth ; vascular effects
HF ; risk factors ; fit ; HF mortaliteit
HF cPGs
lVAS
biomedical ; nonprescribing
black race ;HF ; hospitalization ;HR ; cardiovascular mortaliteit
dopamine ; nesiritide ; pooled placebo group
chart review
Shunt implants ; transseptal catheterisation ; transoesophageal echocardiographic
isoelectric focusing ; RIÎ± ; ser77 ; ser83 ; in vivo phosphorylation sites
NT-probNP ; MR-proANp ; MR-proadm
tNF ; antagonists ; HF ; hospital admissions ; nbDMARDs ; RA
myocardial infarction ; m ; heart failure ;HF
Heart rate reduction ; exercise ; heart failure ; ejection fraction ; beta-blocker
HeartMate II insertion ; HeartMate i implantation
MIs ; lower Killip class
mADIt-cRT ; multicenter Automatic Defibrillator Implantation ; Cardiac resynchronization Therapy ; ncw
serum levels ; brain ; natriuretic peptide ; bp ; creatinine ; natremia
RAS ; hypertension ; nephropathy ; congestive heart failure
functional ; MS ; valve plasty ; degenerative MR ; LV ; disease
n2bus segment ; PEvk
end stage heart failure ; Heart failure ; public health ; europa ; north America
Nicorandil ; mitochondrial dysfunction ; doxorubicin-induced heart failure ; rats ; cardioprotection
HeartMate ; left ventricular assist system ; lVAS ; heart failure
cXL-1020 ; hno ; inactive ; cXL-1051
arterial elastance ; ea ; pulsatile afterload ; heart ; pressure volume relation
pharmacologic management ; acute HF ; adverse event rates ; chronic HF
proteomics ; chromatin-associated proteins ; detergent
heart failure ; mechanical support devices ; Cardiology-cardiovascular Surgery Consensus report ; Heart failure ; progressive disease
heart failure ; implantable cardioverter-defibrillator
Self-care of Heart Failure index ; schenfi ; psychometric profile
atrial fibrillation ; carvedilol ; metoprolol
SDQT ; SDr intervals ;SDr ; index ; ncw ; heart rate variabiliteit
devices ; significant ; gastrointestinal bleeding
heart failure ; follow-up visits
Logistic regression ; death
egFR ; VAD group ; ecmo ;VAD ; renal function
acs ; eseptal ; QRs width
HF ; noncardiologist ; physicians
LV ; ejection fraction ; pcw
diuretics ; morbiditeit ; mortaliteit
congestive heart failure ; verenigde staten
icc occlusion ; co ; twist ; apical rotation ; RS ; RS synchrony ; CS
CHF ; ED visits ; CHF ; intubated
emergency department ; acute heart failure ; Collins
zebrafish ; nucleolin ; genomic reprogramming events
voordelen
gs ;HR ; CV
sst2/low-dose BB ; sst2/high-dose BB
cardiac events
ejection fraction
HF ;AMI ; mortaliteit
exercise ; diet ; exercise ; diet
mortaliteit
nurses ; benefits ; magnet
HF ; drug treatment ; PAf biosynthetic enzymes ; lyso-paf-AT
cardiac magnetic resonance imaging ; t1 mapping ; invasive hemodynamic assessments
HF ; ejection fraction ; pEF
mouse ; hh ; salt loading ; uninephrectomy ; ANG II infusion
Dual RAS ; neprilysin inhibition ; chronic heart failure ; systolic dysfunction ; treatment
t1-mapping sequence ; tidal respiration ; gadolinium-chelate contrast agent
Medicare inpatient ; HF ; admissions ; acute care hospitals ; verenigde staten
idiopathic dilated cardiomyopathy ; tuscany
Morbiditeit ; mortaliteit ;HFpEF ; HF ; EF
DAPc ;dystrophin-associated protein complex ; sarcomeric microstructure
dopamine ; low-dose nesiritide ; acute heart failure ; renal dysfunction ; acute heart failure
catheter ablation ; atrial fibrillation ; heart failure ; ejection fraction
eCG ; congenital accessory pathways ; ion channelopathies ; cardiomyopathy
heart failure ;HF ; risk stratification ; inpatient ; outpatient
conscious ;HF ; pyridostigmine ; basal heart rate ; vagal ; sympathetic control ; heart rate
Modere-strength ; intravenous iron ; exercise tolerance ; heart failure
thropoiesis-stimulating agents ; anemia ; heart disease
bet ; bromodomain-containing protein ;brd ; cardiac tissues
kosten ; QuÃ©bec Health Insurance Board ; kosten ; Ontario Case costing Initiative
mitral valve ; plasty ; degenerative mitral regurgitation
carvedilol ; metoprolol ; heart failure ; devices
HF ;heart failure ; t2d ;Type 2 diabetes ; Skm ;skeletal muscle
public health ; air pollution ; industrial ; cardiovascular health ; hospitalisation ; death
molecular biomarkers ; pathophysiology ; chronic HF
cardiopulmonary exercise ; quality of life score ; muscular strength ; quadriceps force
Myocardial titin hypophosphorylation ; heart failure ; ejection fraction ; rat ; metabolic risk
NT-probNP ; antibodies ; nonglycosylated ; nonterminal epitopes
University of Connecticut Heart Failure Center ; cardiologist ; heart failure
serum creatinine level ; serum potassium level
PD ; weight loss ; diuretic response ; peripheral edema ; functional
echocardiographic ; response ; cardiac resynchronization therapy ; cRT
HeartMate ii lVAD ; CentriMag rVAD
HF ; MI ; ejection fraction ;EF
anemia ; chronic heart failure ;HF
Hum-retn mice ; cardiac mRNA ; inflammatory ; cell adhesion genes ; Retn
chromatin subproteomes ; heart failure ; proteins ; chromatin structure
HFpEF ; ncwt
nbDMARD ; tNF antagonist
voordelen ; structured exercise programme ; heart failure
AF ablation
end-stage heart failure ; mechanical cardiac support
Chronic heart failure ; transforming growth factor ; beta-dependent yield ; functional ; atrial
rv ; intrinsic left ventricular dysfunction
follow-up visits ; follow-up visits
corruptie ; inpatient admissions ; hospital days ; emergency department ; dp
economische ; lVAD
multiparametric echocardiographic score ; cRT
ejection fraction
If-channel inhibition ; hemodynamic status ; exercise tolerance ; heart failure ; preserved ejection fraction
Cardiac ; insulin-resistance ; mitochondrial energy production ; systolic heart failure ; pressure-overload hypertrophy
CHF ; fat
pigs ; inferior vena cava ; icc ; snared ; co
doxorubicin ; ip ; serum resistin ; Hum-retn mice
kosten
rheumatic ; MS ; mva
deactivation

HF ; pyridostigmine ; stroke ; ejection fraction ; cardiac output ; contractility ; left ventricle
myosin binding ; protein-c phosphorylation ; ser23/24 troponin I phosphorylation ;HF
aldosterone receptor antagonists ; morbiditeit ; mortaliteit ; systolic heart failure
uPR effectors ; protein kinase ; r-like ER kinase ;PERk ; calreticulin ; CHOp ; HF tissues
hFrEF ; exercise performance ; resting ; HR ; beta-blocker therapy
echocardiographic ; n-terminal pro-brain natriuretic peptide ; inflammatory markers
cox hazard models ; ESRD ; death ; ESRD ; death ; ESRD
rcrt
heart failure ; heart failure ; nurses ; follow-up ; cardiology ; mortaliteit
heart failure ;HF ; cardiopulmonary exercise test ; anaerobic threshold ;AT
renal dysfunction ; stroke ; myocardial infarction ; heart failure ; CABG
XO inhibition ; cardiomyocyte bioenergetics ; LV ; chronic aCF ; rat
carvedilol ; thromboembolic events ; heart failure ; Î²2-receptor haplotype status
pyridostigmine ; methylatropine ; propranolol ; cardiac sympathovagal balance
PAf ; metabolic enzymes ; heart failure
trastuzumab ; cardiotoxiciteit ; congestive heart failure ; ncw
Phosphodiesterase-2 ; hearts ; beta-adrenergic responses ; cardiomyocytes
lipolysis ; energie expenditure ; natriuretic peptides ;NPs ; CC
cox proportional hazards ; health
ecb ; rhythm control therapy ; AF ; cardiovascular complications ; AF
hearts ; mena ; cardiac injury ; mena ; HF pathophysiology
scn5a transcript ; uPR ; cardiac genes ;HF
AIN oUTCOME ; gls ; index beat ; CV events ; cox proportional hazards analyses
VAD group ; ecmo+VAD group ; ecmo
pacse ; PASp ; downward regression line ; nonsurvivors ; PASp ; pvse
Right ventricular ; vn ; left ventricular assist device ; lVAD
albumin levels ; inflammation ; hepatic function ; lVAD implantation
ST2 ; c ; net reclassification ; discrimination
post-hCT CHF ; hCT ; City of Hope
ischemic ; ischemic heart failure ; biomarkers ; heart failure
infarcted animals ; left ventricle ; end-diastolic pressure ; hg
Women's Health Initiative ; HF
oxygen consumption ; oxygen pulse
dialysis-dependent patients ;HF ; cRT implantation
vn ; pathophysiologic mechanisms ; RV dysfunction
cardiac deaths ; atherosclerotic CAD
Ambient air pollution ; cardiovascular health ; acute myocardial infarction
economische ; NHs ; behavioural-change ; chronic disease ; exercise ; hospital facilities
non-fatal stroke ; heart failure ; follow-up
biomarkers ; molecular dysfunction ; chronic HF
ncw ; kaplan-meier curves ; death ; hospitalization
cRT-d ; significant ; IE ; defibrillator-only therapy ;HR
HR ; HR ; risk stratification
diagnose ; alternatieve treatments ; follow-up
figuur ; diabetes mellitus ; metabolic risk factors ; heart failure ; ejection fraction
therapy ; atrial fibrillation ; atrial tachyarrhythmias ; ATP ; shock therapy
hypoalbuminemia ; postoperative mortaliteit ; left ventricular assist device ; lVAD ; implantation
AMI ; heart failure ; kidney infection ;UTI
cardiopulmonary exercise ; echocardiographic assessment ; myocardial function ; left ventricular filling ; exercise
percutaneous coronary revascularization ; hemodynamically ; intensive care unit ;ICU
speckle tracking ; echocardiography ;STE ; BiVP ; right ventricular pressure overload ;rvp
pathophysiologic mechanism ; renal underperfusion ; renin- angiotensin-aldosterone pathway
omsted County ; Minnesota ; MI diagnosed ; HF
proteomics ; pathway analysis ; pressure-overload-induced heart failure ; attenuation ; mitochondrial-targeted peptides
neurohumoral blockers ; HF
odds ratio ;hazard ratio ; death ;HF ;AMI
CAD ; CAD
vascular endothelial growth factor ; veu ; compensatory hypertrophy ; cardiac failure
left ventricular ejection fraction ; heart failure ; Heart Failure Survey ; israel
death ; medical hospitalization ; HF
icc ; multicenter Automatic Defibrillator Implantation ; trial-Cardiac resynchronization Therapy
Testosterone therapy ; exercise rehabilitation ; chronic heart failure ; testosterone status
Health Buddy Program ; chronic obstructive pulmonary disease ; mortaliteit ; congestive heart failure
RAS ; doppler ultrasonography ; computed tomographic angiography ; magnetic resonance angiography
nicorandil ; significant ; cardioprotection ; apoptotic signaling pathway ; DNA fragmentation ; mitochondrial ultrastructural changes
atrial fibrillation ;AF ; heart failure ;HF ; stroke ; anticoagulation
echocardiographic score ; LV ; reverse remodeling
perk inhibition ; scn5a ; kv4.3 mRNA levels ; na+ channel mRNA splice
bottleneck stent ; myocardial infarction ; antiplatelet medication
sex ; EF ; bNP ; HF ; bNP ; sex ; EF
Trastuzumab ; CHF ; nontrastuzumab ;hazard ratio ;HR
Rad variant ;Q66p ; congestive heart failure ; humans
salt loading ; uninephrectomy ; ANG II infusion ; mouse ; cardiac function ; mice ;HF
Mena expression ;HF ; mena ; cardiac pathophysiology
LVEF ; mortaliteit ; hospitalization ; acute decompensated HF
Fontan failure ; circulatory derangement ; hemodynamic ; portal hypertension ; cardiac output
HF ; index ;AMI
systolic heart failure ; spironolactone
ucp ; na+ channel mRNA splice ; cardiac ; na+ current ; human HF
diuretic efficacy ; neurohormonal activation ; fluid overload
BETs ; transcriptional pause release ; re-activating transcription ; pathological stress
lVAD ; transplantation eligibility status ; patients ; budget
LVEF ; LVEF
apoptosis ; heart failure
functional enrichment analysis ; programmed cell death ; degs
eCG ; bijdrage ; atherosclerotic CAD ; cardiac death
HR reduction
ANS mice ; LV ; lung weight
atrial fibrillation ; Atrial fibrillation ; Stroke prevention
frailty ; heart failure ;HF ; biological phenotype
functional ; MS ; valve plasty ; annular size reduction ; degenerative MR ; LV ; disease
idiopathic dilated cardiomyopathy
right ventricular ; vn ; body composition ; advanced heart failure ;HF
American college of Cardiology ;American Heart association ; RAS ; treatment plans ;RAS
ARNI ; cardiovascular mortaliteit ; hospitalization ; heart failure
quadriceps force
implantable cardioverter-defibrillator deactivation ; heart failure patients
o-cFUs ; cd34 ;vegFR2 ; cells ; mortaliteit ; nondiabetic patients
functional ; MS ; valve plasty ; degenerative MR ; LV ; disease
anaerobic metabolism ; respiratory quotient
exercise training ;HF ; exercise ; therapy
myocardial DD ; high muscle strip ; stiffness ; titin hypophosphorylation
NP measurement ; POc measurement ; NPs
etiology ; comorbidities
high-volume physicians ; readmission rates
financiÃ«le ; intestinal morphology ; absorption function ; CHF
proteins ; cardiac hypertrophy ; proteins ; nucleolin
benefits ; follow-up
Blood pressure ; arm cuff ; stroke volume ; vn ; ejection fraction ; end-diastolic volume ; echocardiography
Kansas City Cardiomyopathy Questionnaire ; ncwt ; HF ; EF ; HFpEF
biventricular support ; hybrid system ; HeartMate ii ; lVAD ; CentriMag ; right ventricular assist device ; rVAD
tricuspid annular plane systolic excursion ; pulmonary arterial systolic pressure ; heart failure ; index ; right ventricular contractile function
fibrosis ; heart failure ; myocardial tissue ; left ventricular tissue ; trichrome blue histologic analysis
bt ; dt ; bt
expenditure ; health per capita ; gross national income ; HF ; la
borderline ; female ; EF
blood pressure control ; lipid-lowering therapy ; smoking cessation ;RAS
SDt ;HFVT ; HFVT ; hNorm ; fixed-rate atrial pacing

AF ; pharmaceuticals ; hFPEF
IEs ; cRT-d ; heart failure ; death
bp ; inhospital mortaliteit
t1-mapping techniek ; diffuse myocardial changes ; heart failure ; contrast agent ; breath-holding
implantable cardioverter-defibrillators ; iccs ; mortaliteit ; cardiac resynchronization therapy ; cRT
ventricular assist device ;VAD ; extracorporeal membrane oxygenation ; ecmo ; renal function ; children
Vascular endothelial growth factor blockade ; beta-blocker therapy ; cardiac function ; angiogenesis ; heart failure
NT-probNP ; plasma ; dyspnea ; left ventricular dysfunction ; ED
contractile function ; LV dilatation ; LV ; end-diastolic pressure ;wall stress ; lung weight
circulating progenitor cells ; c pcs ; endothelial repair ; cardiovascular diseases
HF-acTION cohort ; hgb ; baseline HRQoL ; ncwt
heart ; cardiac hypertrophy ;HF ; fibrosis ; inflammation
Caucasian ; genotyped ; sNP ; ka renal chloride channel gene ; ccnka
HFpEF ; echo-doppler cardiography ; invasive haemodynamic assessment
LV ; diastolic properties ; XO inhibition ; heart failure
RAS- ; Î²-blocker uptitrations ; hFrEF ; HFpEF
cardiac magnetic resonance ; amyloidotic pattern ; multiple myeloma ; osteomedullary biopsy
Low-sodium DASh ; diet ; diastolic function ; ventricular-arterial coupling ; hypertensive heart failure ; ejection fraction
Yorkshire swine ; implanted ; pacemakers ; ventricularly paced ; heart failure
multiparametric echocardiographic score ; reverse remodeling ; cRT
isolated heart rate ;HR ; ivabradine ; systolic heart failure
biomedical treatment ; CHm ; biomedical treatment ; dc ; heart failure
Cardiovascular Outcomes ; Renal Atherosclerotic Lesions ; coRAL ; stenting ;RAS
centrifugal flow pump ; hemocompatibility ; magnetically levitated rotor ; blood-flow paths ; artificial pulse
mitochondrial complex ; post-aac ; phosphocreatine ; ATP
Mediterranean ; Dietary richtes to Stop Hypertension ;DASh ; mortaliteit ; postmenopausal women ;HF
left-to-right interatrial shunting ; heart failure ; ejection fraction
mortaliteit ; heart failure ;HF ; implantable cardioverter defibrillators ; iccs
Physician ; medically managed diseases ;HF
frail ; frail
eplerenone ; HF-ref ; hyperkalemia ; wRF
emergency department ; acute heart failure ; aHF
RM ; discharged ; heart failure
lb ; implantable cardioverter defibrillator-cRT
md
embryonic gene programs ; pathological heart disease ; transcription factors ; gene programs
hFPEF ; cardiac event
sst2/low-dose BB ; sst2/high-dose BB ; cardiovascular events
skeletal muscle ; sarcomere structure ; heart failure ; type 2 diabetes ; epicatechin-rich cocoa
QRs morphology ; cardiac resynchronization therapy ; cRT
PASp ; hg ; pasp ; PASp
heart failure ; severe hypertension ; mitral regurgitation ; significant mitral stenosis ; aggressive medical treatment ; heart failure
POc systems ; NP
mortaliteit ; readmissions ; kosten
lbf ; QRs ; benefit ; implantable cardioverter ; defibrillator-cRT
echocardiography ; cardiac diameters ; cardiac function
medline ;EMBAse ; PsycINFO
significant ; functional capacity
urban academic medical center
ST2 ; cardioprotective signaling ; myocardium ; biomarker ; heart failure ;HF
systolic HF ; cXL-1020 ; left ; right heart ; filling pressures ; systemic vascular resistance ; cardiac ; stroke volume index
cardiovascular death ; stroke ; heart failure ; myocardial infarction
Cardiac-resynchronization therapy ; cmt ; morbiditeit ; mortaliteit ; chronic systolic heart failure ; QRs complex
perk activation ; scn5a ; kv4.3 channel mRNAs ; transient receptor potential cation channel ; m7 ;TRm7) channel mRNA
implantable cardioverter-defibrillator ; Heart Function Clinic ; University Health Network ;Toronto ; Canada
pasp ; pulmonary hypertension ; ventricular contractile reserve
MI ; metoprolol ; plasma ; norepinephrine ; dopamine ; epinephrine
antagonists ; inhibitors ; renin-angiotensin-aldosterone ; sympathetic nervous systems ; CHF
heart failure ; hospital discharge ; readmissions ; follow-up visits
antiplatelet agents ; combinatie ; anticoagulants ; vascular diseases
Fontan failure ; hemodynamically ; heart failure ; systemic vascular resistance ; vn ; index ; cardiac index
myofiber dynamics ; myofiber shortening ; EMd ; dyssynchronous HF
ankle-brachial index ; pulse-wave velocity ; coronary artery ; calcium scores
na+ channels ; unfolded protein response ; unfolded protein response ; ucp ; scn5a ; electric remodeling ;HF
intermacs ; interne Registry voor Mechanically Assisted circulatory Support
international Right Heart foundation Working Group ; right heart failure
cardiac hypertrophy ; pressure-overload ; abdominal aortic constriction ; aac
HF ; risk factors ; HF epidemiology ; SH ; ncw ; rheumatic fever
caloric restriction ;diet ; aerobic exercise training ;exercise ; exercise capacity ; QOL ; obese older patients ; hFPEF
chronic heart failure ;HF ; hemodynamic disorder ; syndrome ; dysfunction
medications ; heart failure ; ejection fraction ; outpatient setting
HFpEF ; diastolic filling time ; heart rate
cardiac myocyte-specific Mena overexpression ;TTA ; gttetMena ; cardiac pathology
allopurinol ; LV contractile function ; efficiency ; XO-mediated ROS ; myofilament ; sensitiviteit
therapy
AF ; heart failure ; financiÃ«le burden
rehospitalization ; Medicare ; hospital claims ; Medicare ; post-acute care transfer policy
heart failure ; refill compliance ; etidronate ; alendronate
AT ; metabolic exercise ; cardiac ; kidney index score
physical activity ; cRF ; HF mortaliteit
et ; HDl-mediated protective effects ; molecular pathways ; chronic heart failure ; chw
physicians ; advanced heart failure ; therapeutic
isolated heart transplant ; ect
follow up body weight ; FM ; fm ; CC
r. Cluster analysis
left ventricular ejection fraction ; left ventricular diastolic end diameter
eccentric ; concentric left ventricular hypertrophy ; heart failure ; ejection fraction
left ventricular ejection fraction ; heart failure ; preserved ejection fraction ;HFpEF
Î²-adrenergic receptor blocker therapy ; myocardial perfusion ; neoangiogenesis ; heart
hgb ; ncw ; scales ; hgb ; exercise ; HRQol
bone morphogenetic protein ; rRNA transcription ; heterochromatic chromatin
placebo ; dopamine ; nesiritide ; decongestion ; renal function
actin ; cytoskeleton ; mitochondrial function ; intermediate metabolism ; glycolysis ;gluconeogenesis ; citrate cycle
elevated resistin ; biomarker ; anthracycline-induced cardiotoxiciteit ; heart failure ; macrophages
extracellular matrix ; left ventricular biopsies ; tissueFAXs ; technology
systolic HF ; Danish Heart Failure database ; ESr ; Danish Registry on Dialysis
left ventricular assist devices ; lVADs ; heart failure ; pump dysfunction ; pump replacement
bp ; diastolic dysfunction
hART ; HFpEF ;HF ; ejection fraction ;HFrEF
techniek ; systolic function ;HFpEF ; long axis function ; exercise
current HF ; mortaliteit ; hazard ratio ; mortaliteit
AAs ;HF ; hyperkalemia ; hypokalemia ; spironolactone
receptors ; g-protein-coupled receptor kinase-2
NT-probNP assay ; epitopes ; glycosylated region
scn5a ; AngII ; hypoxia ; uPR
ST2 ; natriuretic peptide
sst2/high-dose BB ; sst2 ; low-dose BB ; cardiovascular event
anemia ; iron deficiency ; medline ; cochrane Library
neurohormones ; adipokines ; body composition ;cc ; fat free mass ; fm ; fat mass ;FM
cardiac plasma membrane ; s1PR1 ; Î²1ar overstimulation ; heart failure
Sprague-Dawley ; sham ; aCF ; allopurinol
t1 ; myocardial collagen ; myocardial delayed enhancement imaging
saxagliptin ; sitagliptin ; follow-up
magnetically levitated lVAS ; mortaliteit ; Seattle Heart Failure

ncw ; internal consistency ; HFpEF ; krotbach
implantable cardioverter ; defibrillator-cRT ; lbf

follow-up ; etidronate ; raloxifene-treated
chemotherapy ; trastuzumab ; comorbidities ; CHF ; international Classification of Diseases ; healthcare common procedure coding system codes
heart failure ;HF ; therapies ;HF ; left ventricular ejection fraction ; lEF
conscious ; dogs ; tachypacing-induced HF ; cXL-1020 ; contractility
cRT ; hazard ratio
mt
cox proportional hazards ; death ; transplantation ; LV assist device implantation ; heart failure ; hospitalization ; follow-up
Nicorandil ; phosphocreatine ; adenine nucleotides ; mitochondrial oxidative phosphorylation capacity ; creatine kinase activity
intraclass correlation coefficient ; icc ; kappa coefficient ; md
Hospitalized Heart Failure ; Saxagliptin ; sitagliptin ; antihyperglycemic Drugs ; Retrospective cohort Study
race ; exercise training ; chronic heart failure ; Heart Failure ; controleled trial Investigating Outcomes ; Exercise TraiNing ;HF-acTION
biomedical treatment ; CHm ; biomedical treatment ; dCM ; heart failure ; PubMed
Swedish national inpatient Registry ; rehospitalization ; stroke ; myocardial infarction ; heart failure ; caBG
Biventricular pacing ;BiVP ; cardiac output ; co ; cardiac surgery
New York Heart association ;NYha ; chronic heart failure ; ejection fraction ; special access programme
AlphaLISa immunoassays ; antibodies
creatinine ; bNP ; furosemide ; oxygen flow ; dobutamine ; norepinephrine
expression ; mistargeting ; altered regulation ; Rad Q66p ; rGK protein ; efficacy in vivo
Myocyte hypertrophy ; heart failure ; gene expression ; DNA
Catheter ablation ; AF ; compensated hFPEF ; left ventricular ; vn ; ejection fraction
Cardiology ; Cardiovascular Disease Registry ; practice innovation ; Clinical Excellence registry
congestive heart failure ; Midwestern state ; South dakota
sts HH ; TM ; mortaliteit ; discharged ; patients ; heart failure
induced myocardial infarction ; heart failure ; bisoprolol ; vehicle
in-patient follow-up ; health care system
CHF ; cardiac explant
tachycardia ; intravenous atropine ; cardiac vagal tone ; CHF-DNx ; animals
cardiomyocytes ; mechanical ; humoral stimuli ; myocardium
biological phenotype ; deficit index ; medical records
BB therapy ; sst2 measurement ; chronic heart failure ; BB
ehr ; systolic HF ; egFR
pvse ; PASp ; length-force relationship ; rv function evaluation ; LV dysfunction
tunel assay ; apoptotic cells ; tunel-positive cells
functional efficacy ; hno ; donor ; myocardial function ;HF
biventricular support ; rVADs ; explanted
Peritoneal dialysis ;PD ; diuretic resistant volume overload ; heart failure ;HF ; benefit
left-to-right interatrial shunting ; heart failure ; ejection fraction
hno ; donor ; cXL-1020) ; isolated myoctyes ; intact hearts ; heart failure ;HF
Physical examination ; bmi ; weight ; heart rate ; rhythm ; lying ; standing ; blood pressure ; uitcultation ; valvular disease ; pulmonary congestion
myocardial extracellular matrix ; cardiac magnetic resonance t1 mapping ; pathobiology ;pathophysiology
aldosterone antagonist therapy ; chronic advanced heart failure ; post-myocardial infarction ; heart failure ; ejection
Nicorandil ; heart rate ; aortic blood flow ; mitochondrial oxidative stress ; doxorubicin ; cardiotoxiciteit
heart failure ; left ventricular ejection fraction ; spironolactone ; Kaiser Permanente Northern California
SDt ; hwt ; hNorm ; Î²-adrenoceptor blockade ; esmolol
heart failure ; CHAr programme ;Candesartan in Heart Failure assessment of reduction in Mortality ; Morbiditeit
heart failure ; preserved ejection fraction ; hbf ; heart failure ; overweight ; obese
renal dysfunction ; heart failure ;HF ; renal disease ; eRD
echocardiographic score ; LV ; reverse remodeling ; LV ; end-systolic volume
Peripheral artery disease ;PAD ; heart failure ;HF ;HF ;HF ;PAD
heart failure ;HF ; acute myocardial infarction ;AMI ; pneumonia
peripheral muscle pump ; cardiac filling ; exercise ; subpulmonary ventricle ; Font circulation
renal dysfunction ; cardiovascular events ;stroke ; myocardial infarction ; heart failure ; death ; isolated coronary artery bypass grafting
asymptomatic pediatric Fontan ;PF ; catheterization
MS ; MS ; fixed ring
ventricular assist devices ; cardiac nurses ; gastrointestinal bleeding
Lancet ; Anoop Shah ; air pollution ; heart failure ; morbiditeit ; mortaliteit ; elderly
anemia ;HF ; health-related quality of life ; hQol ;HF
cell therapy ; chronic heart failure ; chw ; disease ; explant-derived progenitor cells
dyssynchronous nonfailing ;HF ; canine electromechanics
amerikaanse college of Physicians ; aCP ; anemia ; iron deficiency ; heart disease
exercise ; cell senescence ; active ; malignancies ; cancer ; prostate ; colon ; osteoporosis ; depression ; dementia
follow-up
race ; chronic heart failure ;HF ; exercise training response
histological analysis ; capillary ; coronary perfusion ; ad-flk rats ; ad-c
internists ; cardiologists
shuttle walk test ; body mass ; hand grip strength ; baseline
POc testing ; NP ; ED
troponin t ; n-terminal pro-b-type natriuretic peptide ; biomarker ; heart failure ; atherosclerosis risk
tachycardic response ; methylatropine ; vagal tone ; bradycardic response ; propranolol ; sympathetic tone
acute rv failure ; chronic pulmonary arterial hypertension ; pb ; acute pulmonary embolism
cardiac resynchronization therapy ; cRT ; mild heart failure ;HF ; QRs ; ejection fraction ;EF
fractional flow reserve ; positron emission tomography imaging ; ischemia ; bottleneck stenting ; left ventricle ;LAD
mitochondrial oxidative phosphorylation capacity ; creatine kinase activity ; oxidative stress markers ; DNA fragmentation
cox regression ; spironolactone ; death ; hyperkalemia ; kidney injury
mortaliteit ; mortaliteit ; cardiovascular mortaliteit ;HF hospitalization ; race ; cox ; exercise training
cardiac transplant ; ect ; transplant pool ; transplant
Exercise ; Medical Therapies ; Cardiac Function ; Breath ; Lung congestion ;ACTRN
septum ;systolic ; thickness ; LV ; posterior wall ; interne diameter ; metoprolol
obese ; older ; hFPEF ; caloric restriction ; aerobic exercise training ; VO2
economische ; Patient management Interventions ; Heart Failure ; heart failure
HF registry ; HF ; EF ; HFpEF ;EF
BAT ; pro-brain natriuretic peptide ; HF
HR variabiliteit ; mortaliteit ; AMI ; CHF ;LV dysfunction
neprilysin inhibitors ; natriuretic peptide ; atrial ; natriuretic peptide ; natriuretic peptide
hypoalbuminemia ; albumin concentration
acute rv ; pulmonary embolism ; mortaliteit
electrical activation ; dyssynchronous heart failure ;HF ; electromechanical behavior ; heart
heart failure ;heart team ; cardiologists ; cardiovascular surgeons ; medical staff
Baroreflex sensitiviteit ; time domain ; heart rate variabiliteit ; hv ; CHF-inv ; sham-inv ; sham levels ; renal DNx
bisphosphonates ; alendronate ; etidronate ; significant ; heart failure ; refill compliance
cognitive impairment ; hospitalization ; discharge ; heart failure
HF-acTION ;HF ; ejection fraction ; exercise training
Chinese herbal medicine ;CHm ; dilated cardiomyopathy ; dcm ; heart failure
serum resistin ; women ; anthracycline-containing chemotherapy ; cardiotoxiciteit
sst2 ; BB ; cardiovascular event rate
Rad Q66p ; cardiomyopathy ; l-type
ventricular structure ; geometry ; fiber ;sheet orientation
ncwt-to-SDr ratio ; HFVT ; hwt ; hNorm
renin-angiotensin system blocker ; beta-blocker therapy ; heart failure ; left ventricular ejection fractions
functional electrical stimulation ; peripheral muscles ; endothelial function ; heart failure ; left ventricular ejection fraction
cardiac transplant ; ect
diastolic dysfunction ; pathophysiology ; HFpEF ; non-diastolic abnormalities ; cardiovascular function
EMd ; dyssynchronous HF
hypertension ; compensated HFPEF ; DASh ; sRD ; sodium ; kcal
doxorubicin-induced cardiotoxiciteit ; Hum-retn ; littermate ; resistin ; retn
arrhythmia substrate ;AMI ; HR ; fatal ; arrhythmia events
heart failure ;HF ; HF
HF ;AMI ; pNA ; mortaliteit
hypertension ; hg ; diabetes mellitus ; systolic ; diastolic murmurs
pacse ; PASp ; nonsurvivors ; hFrEF ; HFpEF
epigenetic ;writer ; proteins ;histone acetyltransferases ; epigenetic ;erasers ;histone deacetylases ; cardiac
NT-probNP ; mortaliteit ; acute HF
haematopoietic cell transplantation ; ht ; congestive heart failure ; chw ; ht ; exposure ; anthracyclines
cardioprotective effect ; nicorandil ; hemodynamic alterations ; mitochondrial dysfunction ; doxorubicin
in vivo inhibition ; mir-25 ; antagomir ; cardiac dysfunction ; murine myocardium ; heart failure ; hand2-dependent
carvedilol ; Î²-blocker ; Î²-blocker ; metoprolol ; thromboembolic events ; heart failure
cox regression models ; propensity score ; oral glucocorticoid dosage ; HF ; loop diuretics
albumin ; mortaliteit ; lVAD implantation ;hazard ratio
dyssynchronous HF ; electromechanical delay ; ecd ; myocyte depolarization ; myofiber
Beta blockers ; mortaliteit ; readmissions ; heart failure ; ejection fraction ;HFrEF ; heart rate ;HR
bleeding ; driveline infection ; gastrointestinal bleeding ; debilitating stroke ; Rankin Score
dialysis ;HF ; hospitalization ; mortaliteit ; HF ; hospitalization ; death
functional electrical stimulation ; fes ; exercise capacity ; emotional stress ; endothelial function ; heart failure ; systolic function
ejection fraction ; cardiac index ; inotropes ; inotrope-dependent ; medical ; transplant
systolic heart failure ; QRs ; cmt ; heart failure ; mortaliteit
lipoprotein ;HDl ; endothelial-protective effects ; endothelial cell ; ec ; nitric oxide ;NO
8-fluo-cAMP binding ; phosphomimic ; ser77 ; ser83 mutant ; RIÎ± proteins ; double mutant ; wt ; RIÎ±
significant ; admission to discharge ; older adults ; heart failure ;HF ; Nursing Outcomes Classification ;noc
insulin resistance ; type 2 diabetes ; insulin receptor substrates ;IRs1 ; iRS2 ; insulin-signaling ; cellular metabolism
genes ; degs ; non-ischemic ; ischemic heart failure ; heart failure
hHF ; saxagliptin ; sitagliptin ; antihyperglycemic agents
QRs morphology ; cardiac resynchronization therapy ; resynchronization-Defibrillation ; ambulatory Heart Failure trial ;RAFt
heart ; magnetic resonance imaging ; chelation choices ; heart failure ; arrhythmias
hoog-volume EDs ; discharge ; heart failure ; home ; low-volume ED ; readmissions ; repeat ED visits
anticoagulation ; rate control ; cardiovascular complications ;stroke ; cardiovascular death ; acute heart failure ; atrial fibrillation ;AF
nitroxyl ; hno ; Angeli ; salt ; inotropic ; lusitropic ; vasodilator effects ; vivo ; cAMP
Gene expression ; Bax ; bcl-2 mRNA expression ; heart failure ; bcl-2/Bax
c pcs ; o-cFUs ; circulating ; cd34 ; vEGFR2 ; cd133
ejection fraction ;EF ; pre-PD ; NYha class IIIb ; right ventricular dysfunction
continuous-flow lVADs ; heartMate ii ;HM ii ; HeartWare ; bt ; dt
undiagnosed heart disease ;HF ; surgical palliation
cRT-d ; IE ; IC ; benefit ; cRT-d ; IEs
frailty ; biological phenotype ; weak grip strength ; physical exhaustion ; weight loss
transplant ; PD ; HF volume management ; pb
abnormal liver texture changes ; nodulariteit
biomarker studies ; therapeutic potential
right atrial myxoma ; massive embolism ; pulmonary arteries ; right atrial mass removal ; pulmonary embolectomy
right heart failure ; therapy refractory cardiogenic shock ; heart ; corporeal membrane oxygenation ; ecmo ; cPR ;ICU
cardiac ; VEGF expression ; Akt ; endothelial NO synthase activation ; hearts
heart failure ; left ventricular systolic dysfunction ; BB
post-DASh ; sRD ; brachial ; central blood pressure ; radial arterial tonometry ; cardiovascular function ; echocardiographic
cardiac ; insulin-resistance ; aac ; insulin-stimulated rates ; glycolysis ; glucose oxidation ; plasma membrane translocation ; glucose transporter
Gene expression profile ; gse9128 ; Gene Expression Omnibus ; non-ischemic heart failure ; ischemic samples
pasp ; right ventricular contractile reserve ; pasp
Gene expression profiling ; cardiomyocytes ; jq1 ; drug ; phenylephrine-induced genes
Psychosocial Factors ; Exercise adherence ; Heart Failure ; Patients ; Heart Failure ; Exercise Training ;HF-action
ST2 ; functional capacity ; ambulatory patients ; HF
EF ; EF
cardiovascular diseases ; heart failure ;HF ; HF
bNP ; significant ; bNP ; inhospital mortaliteit
mortaliteit ; mortaliteit
DASh ; diet scores ; mortaliteit ; HF ; Mediterranean diet scores
keletal muscle mass ; appendicular lean mass index ; z-score
CLcnka polymorphism ; heart failure ; glomerular filtration rate ; RENAStur cohort
intubation
black race ; HF ; modifiable risk factors ; exercise performance ; HF ; mortaliteit ; exercise training
hearts ; nucleolin ; chamber patterning ; functional ; cardiac looping ; myocyte differentiation
fat ; lean mass ; fat loss ; enhanced catabolism ; adipose tissue ; cardioprotective ;HF
drugs ; heart failure ; chart review ; biomedical reasons ; nonprescribing
hFrEF ; exercise protocol ; respiratory gas analysis ; baseline
hearts ; TTA ; gttetMena mice ; wild-type littermates ; heart mass ; transgenic mice
raloxifene ; heart failure ; HR
derivation cohort ; coronary angiography ; systolic HF ; unclear etiology ;ejection fraction
arterial elastance ; ea ; end-systolic elastance ; ees ; ventricular-arterial coupling ; ees
heart failure ; left ventricular ejection fraction ; fes ; exercise capacity ; emotional status ; endothelial function ;HFpEF
extracorporeal life support ; bridging therapy ; acute ischemic right heart failure ; refractory cardiogenic shock ; reperfusion therapy
HF met reduced ejection fraction ;HFrEF ; treatment ; HF met preserved ejection fraction ;HFpEF
Cells ; angiotensin ii ;AngII ; hypoxia ; activators ; scn5a mRNA ; splicing ; overexpress ; scn5a variants
rhythm control therapy ; rhythm control therapy ; antiarrhythmic drugs ; catheter ablation ; electrocardiographic device ; rhythm
expenditures ; noncardiovascular diagnoses ; implantable cardiac arrhythmia devices ; noncardiovascular drugs ; rate-control group
follow-up visits ; hospital quality improvement ; follow-up visits
contractility ; ventricular-arterial coupling ; SV ; ivabradine-treated patients
power spectral analysis ; low-frequency ;high-frequency ;LF ;HF ; CHF-inv ; sham-inv ; sham levels ; DNx

cardiac magnetic resonance ; hbf ; biomarker ; hbf
myocardial DD ; collagen deposition ; titin modification ; obese ; diabetic ; zSF1 rats ; heart failure ; ejection fraction
HF-actie ; left ventricular ejection fraction ; New York Heart association ; wh ; exercise training
significante event rates ; acute myocardial infarction ; congestive heart failure ; adverse events
natriuretic peptide ; n-probNP ; misdiagnosis ; heart failure ;HF
Macrophages ; cardiomyocytes ; Hum-Retn mice ; doxorubicin ; hRetn ;human resistin ; mRNA ; protein expression
plasma ;HF ; immunoreactive ; NT-probNP ; NT-probNP
eh ;HFpEF ; HF ; EF ;HFrEF ; hFrEF ; therapy
sympathetic tone ; parasympathetic tone ; heart rate ; metoprolol ; atropine
FM ; plasma NPs ; adiponectin ; fm ; NPs ; adiponectin ; followup
lVADs ; CF devices ; HeartMate i devices ; thoratec Corp ; Pleasanton ; calif ; hVAD ; devices ; HeartWare intl ; Inc ; Framingham ; Mass
beat-to-beat QT interval ; eCGs ; horizontal pacing ; esmolol ; isoprenaline ; atropine infusion
CAD ; angiography ; systolic HF ; significant
frailty ; Health ABC Short Physical performance Battery ; hb Battery ; Gill index ;HF
HF ; QRs prolongation ; LVEF ; ncw ; reverse remodeling ; benefit ; LV systolic dysfunction
HF ; t2d ;ERC ; treadmill ;VO2max ; oxygen consumption ; Skm biopsies
percutaneous revascularization ; angioplasty ; stenting
hospital ; gastrointestinal bleeding ; incessant ventricular tachycardia storm ; terminal heart failure
chronotropic response ; heart rate ; exercise ; baseline ; follow-up tests ; heart rate ; exercise
cardiac tissue ; mice ; sham-operated ; jq1 ; vehicle ; BET inhibition ; pathological cardiac gene expression programme
epigenetic readers ; cardiac biology ; cardiac gene control ; chromatin-dependent signal transduction ; pathological gene expression ; HF progression
cox-proportional hazard ; negative binomial regression models
follow-up ; death ;heart failure ; sudden death ; noncardiac ; cardiac transplant
oxygen consumption ; v2max ; resting ; HR
admission ; NT-probNP ; ED ; acute HF diagnosis
hand2 ; pressure-overload-induced hypertrophy ; fibrosis ; ventricular dysfunction ; fetal gene program
systolic blood pressure ; left ventricular ; vn ; hypertrophy ; AT ; AN ; AS ; ANS
rv ; lVAD insertion ; cardiogenic shock ; myocardial infarction ; chronic decompensated heart failure
PF cohort ;New York Heart association ;SAF ;PF
HF ;AMI ; odds ratio ; CI
EDs ; heart failure ; ED
Turkey
Western Australian ; administrative health ; HF ; index ;AMI
high-volume physicians ; mortaliteit ; low-volume physicians ; low-volume hospitals

science ; treatment ; older adults ;HF
free-breathing pulse sequence ; myocardial t1 ; swine model ; tachycardia-induced heart failure
non-frail ;HR ; frailty ;HR ; Gill index ;HF
died ; non-survivors
Î²-AR stimulation ; catecholamine infusions ; rats ; pde2 expression ; cAMP hydrolytic activity ; blunted cardiac Î²-AR responsiveness
Xanthine oxidase ;XO ; left ventricular ; vn ; myocytes ; volume overload ; vn ; mitral regurgitation ; aortocaval fistula ; acf
obese ; zSF1 groups ; heart failure ; preserved ejection fraction ; lung weight ; left ventricular ejection fraction ; left ventricular DD
chronic PAH ; hospitalized ; rv ; decompensation ; rv failure management ; pAH
Chronic heart failure ; chw ; aanemia ; insulin resistance ; autonomic dysbalance ; cardiac cachexia
heart failure ; preserved ejection fraction ;HFpEF
inhibitor ; jq1 ; BETs ; chromatin ; RNA polymerase ii ;Pol II
ischemic-hypertensive cardiomyiopathy ; angina ; inducible myocardial ischemia ; coronary arteries
intestinal dysfunction ; intestinal barrier ; inflammatory state ; catabolic ;anabolic imbalance ; cardiac cachexia ; CHF
RA ; methotrexate ; tNF antagonist ; non-biological disease ; antirheumatic drug ; nbDMARD
cyclic adenosine monophosphate ; cAMP ; augmented cyclic guanosine monophosphate ; cgm ; hearts
cox proportional hazards regression ; IE ; acute coronary syndromes ; coronary interventions
miRNAs ; noncoding RNAs ; binding ; messenger RNA
catheter ablation ; atrial fibrillation ;AF ; heart failure ; preserved ejection fraction ; hbf
HFpEF ; ivabradine ; placebo
mortaliteit ; healthcare utilization ; care management ; telehealth ; congestive heart failure ; chronic obstructive pulmonary disease ; diabetes mellitus
heart failure ;HF ; acute myocardial infarction ;AMI ; pneumonia ; pNA
pathophysiology ;HF ; medical management ; pathophysiologic state
NPs ; heart failure ; pulmonary embolism ; diabetes ; chemotherapy
cardiac c-Kit ; cells ; cardiac ; explant-derived cells ; cardiac functions ; myocardial infarction
sphingosine-1-phosphate receptor ; s1PR ; Î²1-adrenergic receptor ;Î²1AR ; g-protein-coupled receptors ; heart
EF ; lcx ;LAD ; stenting ; left ventricle ; lcx ;LAD
signalling cascades ; microRNAs ; bHLh transcription factor ; hand2 ; postnatal mammalian myocardium ; embryonic gene programs ; heart failure
BET ; bromodomain proteins ;BETs ; acetyl-lysine reader proteins ; HF ; HF
cardiac function ; echocardiography ; diastolic dysfunction ; systolic dysfunction ; ejection fraction
hART ; New York Heart association ;NYha ; HF ; self-management counseling ; death ; HF
mva ; surgical ring implantation ; leaflet motion ; leaflet resection ; edge-to-edge anastomosis
eh ; LV compliance ; vn ; end-diastolic volume ; LV ; end-diastolic pressure ; hg ; Î² coefficient
e-septal ; pcWP
Rad Q66p ; inhibitory actions ; Rad ; cav1.2 ; cav1.3 ; l-type channel isoforms ; heart
atrial fibrillation ; carvedilol ; metoprolol ;HR
ERC ; DAPc ; protein levels ; sarcomeric microstructure ; Skm ; myofibre regeneration
gs ; LVEF ; sa ; CV ; benefit ; echocardiographic systolic parameters ; AF
pharmacological treatment ; device consideration ; left ventricular function assessment
Nordic walking ; cardiac rehabilitation ; functional capacity ; heart failure
Bradycardia ; intravenous metoprolol ; cardiac sympathetic tone ; rabbits ; sham-inv ; CHF-DNx
blood transfusions ; iron ; erythropoiesis-stimulating agents ; adults ; anemia ; congestive heart failure ; coronary heart disease ; transfusion
erythropoiesis-stimulating agent therapy ; benefits ; venous thromboembolism
l-type voltage-gated ; ventricular action ; excitation-contraction ; ec ; coupling ; myocardium
heart failure ;HF ; tumor necrosis factor ; tbf ; tn ; antagonists ; benefit ; HF
oxygen uptake ; metabolic exercise ; cardiac ; kidney index score ; HF index
genetic ; CHF ; predictive ; curve ;AUc ; genetic ; abc ; clinical ;AUc
chronic myocardial ischemia ; stent ; polytetrafluoroethylene tube
black race ; mortaliteit ; hospitalization ;hazard ratio ;HR ; cardiovascular mortaliteit ;HF ; hospitalization ;HR
Centers voor Medicare and Medicaid Services ; cms ; hospital ; mortaliteit ; readmission rates ; penalties
Î²-blockade ; disease progression ; cAMP-dependent protein kinase ; pka ; Î²-adrenergic receptor activation
right heart ; circulatory failure ; right heart
HF
Grading of recommendations assessment ; development and evaluation ;GRADe
aldosterone antagonism ; heart failure ; aldosterone ; neurohormone ; electrolytes ; heart failure ; systolic dysfunction
AT1 receptors ; neprilysin blocks ; renin-angiotensin-aldosteron ;RAS ; vasodilatory ; diuretic effect ; natriuretic peptides
bp ; glomerular filtration rate ; hypertension ; transmitral e-wave ; diastolic mitral annular velocity
ivabradine ; exercise capacity ; left ventricular filling ; heart failure ; preserved ejection fraction ;HFpEF
medication ;nonadherence ; salt intake
HR variabiliteit ;turbulence ; HR variabiliteit ;turbulence ; cardiac patients
dopamine ; low-dose nesiritide ; renal function ; acute heart failure ; renal dysfunction
hm ii ; HeartWare ; economische ;HM ii
death ; glomerular filtration rate ;odds ratio
creatinine ;hazard ratio ; significant ; post-transplant mortaliteit
lVAD ; surgery ; albumin levels ; hypoalbuminemia ; surgery
pathophysiological
cox proportional hazard ; follow-up ; physician ; discharge ; death ; urgent all-cause readmission
CAD ; diameter stenosis ; left main ; CAD ; CAD ; proximal left anterior descending artery
heart failure ; acute myocardial infarction ; acute myocardial infarction ; Western Australia
Randomized aldactone evaluation Study ; chronic advanced heart failure ; aldosterone antagonist ; spironolactone ; mortaliteit
mechanism ; annular size reduction ; surgery ; diastolic mitral valve tethering ; anterior leaflet opening ; papillary muscles ; left ventricular dilatation
hypertensive HFPEF ; sodium-restricted DASh ; diet ; ventricular diastolic function ; arterial elastance ; ventricular-arterial coupling
signal transduction cascade ; transcription factors ; cardiomyocytes ; transcription factors ; epigenetic changes ; chromatin structure
CHF ; ht ; polymorphisms ; anthracycline metabolism ; homeostasis ; anti-oxidant defence ; myocardial remodelling
ecs ; HDl ; phosphorylation ; eNOS-Ser ; eNOS-Thr ; PKc-Î²i-Ser
ct ; sterf ; HF ; hospitalization ;hazard ratio ; LVEF
heart failure ; myocardial collagen ; heart failure
administratie ; Alberta ; discharged alive ; hospital ; heart failure
mouse ; ventricular myocytes ; sarcomere ; Î¼mol ; ca(2+) transient
sts ;HH ; hm ; TM ; sts ; TM
PASp
complications ; implantation ; lVAD therapy ; transplantation eligibility status ; device ; bt ; dt ; medical therapy
beta1-adrenergic receptor ; sphingosine-1-phosphate receptor ; s1PR ; reciprocal downregulation ; cardiac hypertrophic response ; heart failure ; s1PR1 ; cardiac gene therapy
radial artery tonometry ; PH ;ICU
cardiomyocytes ; pde2 activity ; cgMP ; nitric oxide donors ; pde2 inhibition ; Î²-AR responsiveness
ejection fraction ; b-type natriuretic peptide ; heart failure ; inhospital outcomes ; get With the Guideline-Heart Failure Registry
Breast cancer ; Medicare coverage ; breast cancer ; chemotherapy ; EER-Medicare ; Texas Cancer Registry-Medicare
eRK1/2 ; signalosome complex ; scaffold protein ; kinases ; sequential phosphorylation
magnetically levitated centrifugal-flow chronic lVAS
l-dko ; cardiac ; iRS1 ; iRS2 proteins ; heart failure ; cardiac energy metabolism ; p38Î± ; mitogen-activated protein kinase
heart failure ; treatment
hospitals ; heart failure ;HF ; acute myocardial infarction ; pneumonia
carvedilol ; metoprolol ; implantable ; cardioverter-defibrillator therapy ; MAD-cRT trial ; multicenter Automatic Defibrillator Implantation ; Cardiac resynchronization Therapy
Caloric restriction ; aerobic Exercise Training ; Peak oxygen Consumption ; Older ; Patients ; Heart Failure ; ejection Fraction
ventricular assist devices ; lVADs ; chronic end-stage heart failure ; bridge to transplantation ; bt ; transplant-ineligible patients ; destination therapy ; dt
right ventricular-pulmonary arterial coupling ; pulmonary vascular resistance ; right ventricular ejection fraction
implanted left-to-right interatrial shunt ; haemodynamic ; heart failure ; ejection fraction
r ; heart failure ; bisphophonates ; crude RR ; nc ; hazard ratio ;HR
abc ; red blood cell transfusion ; hemoglobin threshold ; hemoglobin levels ; coronary heart disease
Medicare ; Centers voor Medicare ; Medicaid Services
acute heart failure ; renal dysfunction ; dopamine ; low-dose nesiritide ; decongestion ; renal function ; diuretic therapy
Rhythm control therapy ; AF ; atrial structure ; function ; sinus rhythm ; delayed rhythm control ; rate control
ncwt ; New York Heart association ; HFpEF ; HF ; EF
nicorandil ; doxorubicin-induced heart failure ; rats ; hemodynamic perturbations ; mitochondrial dysfunction ; antitumor activity
guideline ; heart failure ; Clinical practice Guideline ; pg ; heart failure ;HF
HF ; body composition ;skinfold thickness ; dual-energy X-ray absorptiometry ; echocardiography ; blood testing
cardiac ; insulin-resistance ; mitochondrial oxidative metabolism ; metabolic ; cardiac hypertrophy ; energy deficit ; hypertrophy ; heart failure
Tools voor economische analysis ; Patient management Interventions ; Heart Failure ; kosten-efectiveness ; disease management programs ; heart failure
Rad ; rGK ; rem ; rem2 ; Rad ; Gem ;Kir ; monomeric g proteins ; ventricular action ; ec coupling ; cardiac l-type channel activity
breathing control ; cardiac arrest ; humans ; pulseless ventricular fibrillation ; pbf ; cardioverter-defibrillator device
mechanism ; diastolic mitral valve tethering ; anterior leaflet opening ; papillary muscles ; left ventricular ; vn
pathophysiology ; heart failure ; preserved ejection fraction ; hbf ; myocardial extracellular matrix accumulation
cox model analysis ; PASp ; exercise ;hazard ratio ; pasp
Oral glucocorticoids ; HF ; HR
HFPSI ; death ; medical hospitalization ;HF ; clinic outpatients ; HF ; health systems
HR ; ivabradine group ; Ea ; TAC ; placebo
get With the Guidelines-Heart Failure ; HF ;EF ; borderline ;EF ; EF
VO2 ; lean body mass ; thigh muscle ;intermuscular fat ratio
testosterone supplementation ; exercise rehabilitation ; health outcomes ; CHF ; low testosterone status
follow-up ; ethnic groups ; CHm ; adjunctive treatment ; dc ; heart failure
carvedilol ; metoprolol ;hazard ratio ;HR ;CI
acetylcholinesterase inhibitor ; pyridostigmine ; sympathovagal balance ; cardiac remodeling ; cardiac function ;HF ; myocardial infarction
re-hospitalization ; admissions
cardiac arrest ; cardiopulmonary resuscitation ; cp ; posterior wall infarction ; cardiac centre
heart failure ;HF ; ejection fraction ; rEF ; renin-angiotensin system ;RAS ; Î²-blockers ; doel dose ; mortaliteit ; readmissions
ucp ; scn5a ; ventricular systolic HF ; tissue samples ; induced pluripotent stem cell-derived cardiomyocytes ;hiPSc-CMs
type 2 diabetes ; saxagliptin ; sitagliptin ; pioglitazone ; sulfonylureas ; insulin products
aCP ; erythropoiesis-stimulating agents ; anemia ; congestive heart failure ; coronary heart disease
hyperkalemia ; mineralocorticoid receptor antagonists ; race ; mineralocorticoid receptor antagonists ; heart failure ;HF
pde superfamily ; pde2 ; cgMP ; cAMP hydrolysis ; negative cross talk ; cgMP ; cAMP signaling
mitochondrial-targeted antioxidant ; Szeto-schiller ; ss ; cardiac function ; proteomic remodeling
cardiac sympathetic activity ; i-meta-iodobenzylguanidine ; i-miBG ; Î²-blocker
pvse ;longitudinal RV fiber shortening ; pasp ;force ; RV ; in vivo RV ; length-force relationship
coprimary end points ; urine volume ; decongestion end point ; serum cystatin c ; enrollment ;renal function end point
brain natriuretic peptide ; bNP ; bNP ; bNP
LVEF ; sterf ; HF ; hospitalization ;hazard ratio
Swedish web-systeem for enhancement and development of evidence-based care ; Heart disease ; Recommended Therapies registry ; primary isolated CABG ; stockholm
bbp ; n-probNP ; midregional proANp ; m-proANp ; adiponectin ; CHF ; bmi ; FM
MI ; HF
carvedilol ; von Willebrand factor ; metoprolol ; Î²2-adrenergic receptor haplotype
ec ; HDl ; phosphorylation ; eNOS-Ser ; phosphorylation ; eNOS-Thr ; HDl
HF ;HF ; EF ; HF ; EF ; HF ; mix ; HF ; MI
ctnt ; NT-probNP ; aRIC HF ; abcs ; NRIs
cardiovascular events ; sst2 status ; BB dose ; metoprolol succinate
RESeARCH DESIGN ; Medicare ; older patients ; acute care hospital ;HF ;AMI ; pNA
cochrane Effective practice ; Organisation of Care Taxonomy
mouse ; heart failure ;HF ; hypertensive heart disease ; hh ; pathophysiology ; hh
coPD ; CHF ; cRF ; icc ; kappa coefficients
left ventricular longitudinal systolic strain ; gls ; left ventricular mechanics ; cardiovascular ;CV ; atrial fibrillation ; f
implantable cardioverter-defibrillator deactivation ; implantable cardioverter-defibrillator shocks
heart failure ; myocardial function ; ventricles
implantable ; cardioverter-defibrillator deactivation ; implant ; end-of-life
heart failure ; left ventricular ejection fraction ; aerobic ; dynamic resistance training ; lower limbs
mouse Rad ; murine ; human Rad ; Q66p ; l-type currents ; cav1.2 ; cav1.3 ; wild-type Rad
cRT ; hazard ratio ; 95% confidence interval ;CI
fit ; unfit ; cRF ; fit ; unfit ; overweight ; body mass index ; obese men
left ventricular ejection fraction ; egFR
kosten ; rhythm-control ; rate-control
medications ; medical records ; performance measurement systems
ethically ; pediatrics ; religious beliefs ; legale majority
Medicare Patient Safety monitoring system ; mms ; adverse event rates ; patients ; hospitalized ; acute myocardial infarction ; congestive heart failure ; pneumonia ; surgery
sarcoplasmic reticular ;SR ; ca(2+)-uptake ; protein ; SR ; ca(2+)-pump ; phospholamban ; infarcted hearts ; metoprolol
HFPSI ; blood urea nitrogen ; b-type natriuretic peptide ; New York Heart association ; diabetes status ; atrial fibrillation ;flutter
Timeup ; go ; tug ; chronic obstructive pulmonary disease ; coPD ; chronic heart failure ; ncw ; chronic renal failure ; rbf
RM ; home telemonitoring ; mt ; implanted monitoring devices ; medical ; telephone support ; sps ; human-to-human contact ;HH ; human-to-machine interface ; hm
heart failure ;HF ; plasma ; natriuretic peptide ; bp ; ejection fraction ;EF ; HF ; sex
gs ; left ventricular ejection fraction ; lbf ; systolic mitral annulus velocity ; sa ; CV events
HF ; LVEF ; long-term mortaliteit ; LVEF ; LVEF ; long-term mortaliteit
exercise ; intramuscular testosterone supplementation ; chronic heart failure ; chw ; low testosterone status
cox regression analysis ; beta-blockers ; beta-blockers ; antitachycardia pacing ; aTP ; shock therapy
walking ; Minnesota ; quality of life
congestive heart failure visits ; ED
angiotensin-converting enzyme inhibitors ;angiotensin receptor blockers ; Î²-blockers ; heart failure ; ejection fraction
Rats ; hearts ; caspase-3 activity ; phosphocreatine ; adenine nucleotides ; cytochrome c ; bcl2 ; Bax ; caspase 3 expression
right ventricular pacing ; gene expressions ; Bax ; bcl-2 ; Caspase-3 ; ncw- pcr ; interventricular septum biopsies ; beagle dogs ; heart failure
sodium-restricted dietary ; hypertension ; diet ;DASh ; sRD ; left ventricular diastolic function ; arterial elastance ; ventricular-arterial coupling ; hypertensive hbf
medication ; physical therapy ; implantable defibrillators ; circulatory support ; transplantation ; heart failure ; therapies
cd34 ;vegFR2 ; cells ; functional capacity ; 10-cell ; cd34 ;vegFR2 ; cells ; VO2
arginine vasopressin ; aVP ; physiologic ; CHF ; aVP ; vasopressin receptor antagonist therapy ; CHF
treatment ; outpatients ; heart failure ; ejection fraction
aerobic ; resistance ; voordelen ; exercise capacity ; muscle strength ; cardiac ; n-probNP ; inflammatory ; i6 ; hscrp
heart failure ; myocardial infarction ; m ; Î²-adrenoceptor blockade ; infarcted rats ; metoprolol
resting tension ; fpassive ;sarcomere length ; muscle strips ; kcl-KI treatment ; titin ; extracellular matrix ; fpassive
CHF ; anthracycline exposure ; stem cell source ;allogeneic ; follow-up
case-fatality rate ; concurrent HF ; concurrent HF
readmission ; all-cause readmission ; acr ; Potential Preventable Readmission ; pb ; Centers voor Medicare ; Medicaid ; 30-day readmission ; cms
metoprolol ; carvedilol ; sympathetic activity ; von Willebrand factor
acute HF ; RELAx-aHF ;ASTRONAUT ; PRONTO ; patient enrollment
HF ; international Classification of Diseases ; Ninth revision ; Clinical Modification codes ; discharge diagnosis
pulmonare capillary wedge pressure ; hg ; sd ; hg ; right atrial pressure ; pulmonary arterial pressure ; pulmonary resistance
Rad ; ncwp ; gating movement ; wild-type Rad ; ncwp ; l-type channel inhibition ; rGK proteins
SS20 ; heart failure ; proteomics ; cytoskeleton pathways ; SS20 ; mitochondrial ; metabolic pathways
aortic insufficiency ;AI ; mechanical circulatory support ; continuous flow ;cf ; left ventricular assist devices ; lVADs ; pulsatile devices
pyridostigmine ; coronary artery ligation ; cardiac vagal ; sympathetic tone ; cardiac remodeling ; left ventricular dysfunction ;HF
discharge ; follow-up visits
heart failure ; end stage ; refractory ; terminal heart failure
heart failure discharges ; University of Connecticut health Center ; patients ; follow-up
New York Heart association ;NYha ; Class II Heart Failure ; eplerenone ; Placebo ; Heart Failure Medicines ;EMPs-HF Study
echocardiograms ; left ventricular base ; midpapillary ; apex ; baseline ; icc occlusion ; BiVP ; STE analysis ; twist ; apical ; basal rotations ; CS ; RS
drugs ; RAas ; direct renin inhibitors ; endopeptidase inhibitors ; vasopeptidase inhibitors ; angiotensin receptor blockers
acute heart failure ;HF ; pharmacologic ; therapeutics ; calcium-sensitizing agents ; antagonists ; endothelin ; vasopressin ; adenosine
HF ; phenylephrine ; haemodynamic stress ; transverse aortic constriction ;TAC ; jq1 ; cardiac hypertrophy
Muscle aerobic capacity ; postexercise phosphocreatine resynthesis ; Fontan
i-miBG ; cardiac washout ; carvedilol ; metoprolol treatment ; Î²2-adrenergic receptor haplotype
treatment ; acute myocardial infarction ;AMI ; heart failure ;HF ;AMI
h-dko ; ventricular mass ; cardiac apoptosis ; fibrosis ; Akt ; voorkhead box ; o-1 ; cardiac metabolic gene expression ; ATP content
bottleneck stent ; proximal left anterior descending ;LAD ; proximal circumflex artery ; lx ; proximal LCx ; mid LAD
hospitalized heart failure ; hHF ; dipeptidyl peptidase-4 ; dp-4 ; inhibitors ; antihyperglycemic agents
multivariable cox modeling ; Heart Failure Patient Severity index ;HFPSI ; University of Michigan ;HF clinic ;UM cohort
pde2 overexpression ; cardiomyocytes ; cAMP ; l-type ca2 ; inotropic effect ; Î²-AR stimulation ; basal contractility
ATP ;HR ; shock therapy ;HR
Cardiac resynchronization therapy ; ct ; dialysis-dependent patients ; heart failure ;HF ; benefit ; ct ; dialysis
cardiorespiratory fitness ; rbf ; body mass index ; heart failure ;HF ; mortaliteit ; cardiovascular risk factors ;HF ; mortaliteit ; fit ; unfit men
eplerenone ; hyperkalemia ; renal function ; EMPHASIS-HF ; eplerenone ; Mild Patients Hospitalization ; SurvIval Study in Heart Failure
Heart rate ;HR ; cardiac patients ; acute myocardial infarction ;AMI ; congestive heart failure ; ecb ; left ventricular ;LV
neonatal rat ; ventricular cardiomyocytes ; chronic insulin exposure ; iRS1 ; iRS2 proteins ; insulin action ; mechanism ; cardiac dysfunction ; insulin resistance ; type 2 diabetes
echocardiograms ; left ventricular midpapillary level ; atrioventricular delay ; vd ; interventricular delay ; vd ; ste analysis ; circumferential strain ;CS ; radial strain ; rms
New York Heart association ;NYha ; functional class III HF ; ejection fractions ; chronic stable ; guideline-directed medical therapy ;GDt ; verenigde staten ; Canada ; europa
non-LBbb ; QRs ; QRs
dyssynchronous HF ; myofiber shortening ; septum ; myofiber ; stretch rate ; late-activated lateral wall
label-free shotgun ; proteomics ; proteomics ; transverse aortic constriction ;TAC ; heart failure ; signaling pathway ; ingenuity pathway analysis
c-Kit+ cells ; growth factor-Î² ; tbf-Î² ; mesenchymal transition markers ; pluripotency markers ; shams
pka ; subunits ; type II regulatory ;RIiÎ± ; catalytic ; cÎ± ; subunit expression ; rIIÎ± ; ser96) ; cÎ± ; phosphorylation ;HF
hFrEF ; left ventricular ejection fraction ; HFpEF ; left ventricular ejection fraction ; Î²-blocker ; index HF
cross talk ; g-protein-coupled receptors ; mouse hearts ; Î²-adrenergic receptor ; rat ; postischemic heart failure
concentric remodeling ;cr ; concentric hypertrophy ;CH ; left ventricular ; vn ; remodeling ; heart failure ; preserved ejection fraction ;HFpEF ; eccentric hypertrophy ; eh
weight ;SD ; diet group ;SD ; exercise group ;SD ; exercise ; diet group ;SD
RV dysfunction ;hazard ratio ; cachexia ;hazard ratio
resting ; HR ; follow-up ; VO2max ; resting ; HR
tbf-Î² inhibition ; c-Kit ; cell phenotype ; function ; vitro ; cardiac progenitor function ; cell expansion
NT-probNP ; inflammatory biomarkers ; hscrp ; IL 6 ; hscrp
BETs ; neurohormonally induced heart disease ; nanomolar doses ; jwt ; phenylephrine-mediated hypertrophy ; cardiomyocytes ; pathological gene induction
BAT ; functional status ; exercise capacity ; n-terminal pro-brain natriuretic peptide ; heart failure ; hospitalizations ; gtm-treated wha ; functional class III HF
activation ; PKc-Î²II ; HDl ; malondialdehyde ; HDl ; nyha-IIIb ; HDl ;healthy
MLHF ; exercise ; diet ; exercise ; diet
nonpace ; non-DNx ; stam-innervated ; stam-inv ; nonpace ; DNx ; sham-DNx ; pace ; non-DNx ; ncw-inv ; pace ; DNx ; ncw-DNx
hbc Battery score ; HF risk ; Health ABC ; HF model ; hb ; SD ; significant ; death ; hb
ejection fraction ; frail ; biological phenotype ; death ; frailty ; deficit index ; death
hemoglobin ; hgb ; HRQol ; HRQol ; Heart Failure ; Exercise Training ;HF-acTION
Atrial Fibrillation ; congestive Heart Failure ; health ; expenditures ; QuÃ©bec ; rhythm ; rate-control ; treatment
heart failure ; myocardial ischaemia ; bradyarrhythmias ; valvular regurgitation ; pulmonary embolism ; infection ; renal dysfunction
calcineurin ; nfat signalling ; mir-25 expression ; helix-loop-helix ; bHLh ; transcription factor ; hand ; mouse ; myocardium
pss ; btes ; exercise time ; pss ; btes
NT-probp ; cutoff point
fractal scaling exponent
diastolic function ; diastolic filling ; relaxation ;viscoelastic ; passive ;stiffness ; doppler mitral inflow velocity ; e-wave
heart failure ;HF ; ventricular tachycardia ;HFVT ; HF ; VT ;HFVT ; structurally normal hearts ; hNorm
gs ; cox model ; chronic heart failure ; hypertension ; diabetes ; prior stroke score ; glomerular filtration rate ; LVEF ; sa ; CV events
VAD ; ventricular assist device ; ecmo ; extracorporeal membrane ; oxygenation membrane ; ecmo ; ecmo ; VAD
ischemic events ; ii ; ischemic cardiomyopathy ; icc ; cardiac resynchronization therapy ; defibrillator ; cRT-d
heart failure disease management ; treatments ; health care system
resistin ; heart failure ; mouse ; murine resistin ; transgenic ; Retn gene ; hum-retn mice ; inflammation-stimulated resistin ; humans
angiotensin-converting enzyme inhibitors ;angiotensin receptors blockers ; Î²-blockers ; devices
TTA ; tgtetMena ; cardiac injury ; ejection fraction ; heart dilatation ; hypertrophy ; transverse aortic constriction ;TAC
resynchronization-Defibrillation ; ambulatory Heart Failure trial ; implantable cardioverter ; defibrillator-cRT ; significant ; mortaliteit ; heart failure hospitalization
heart failure ; italiÃ« ; confirmatory factor analysis ; cfa ; schfi ; Self-care Maintenance ; Self-care management ; Self-care Confidence
mwt ; NYha class ; HFpEF ; hFrEF ; therapy ; HFpEF ; death ; HF hospitalization
renal dysfunction ; chronic obstructive pulmonary disease ; diabetes ; peripheral vascular disease ; left ventricular ejection fraction ; iCD shocks ; follow-up ; ischemic cardiomyopathy ; male sex
Raf-MEK1/2-ERk1/2 scaffold proteins ; cardiac remodelling
CHF ; SD testosterone ; nmol ; exercise ; testosterone ; placebo groups
functional MS ; LV ; dilatation ; treatment ; heart failure ;HF ; LV ; functional MS ; HF ; MR ; degenerative mitral valve
New York Heart association ; ncwt ; ncwt ; symptom domains ; Spearman correlations ; HF ; EF ; HFpEF
angiotensin converting enzyme inhibitor ; angiotensin-receptor blockers ; Î²-blockers ; heart failure
c57b ; ANG II infusion ; as ; ANG II infusion ; uninephrectomy ; ANG II infusion ; salt loading ; as ; ANG II infusion ; uninephrectomy ; salt loading
early transmitral blood flow velocity ; tissue ; doppler ; early diastolic mitral annulus velocity ; pulmonary capillary wedge pressure ; pcp ; decompensated systolic heart failure ;HF
systolic indices ;LV ; ejection fraction ; LV strain ;strain rate ; systole ; diastolic indices ; strain rate ; diastole ; early transmitral flow ; sinus rhythm ; follow-up
VO2 ; exercise ; body mass ; diet ; body mass
HF ; confidence interval ; icc ; early-onset HF ; HF
AMI ; hospital ; hospital Compare ; dying
Mass spectrometry ; circulating ; NT-probNP ; physiological proteolysis ; pro2-leu3 ; leu3-gly ; pro6-gly7
ctnt ; NT-probNP ; ctnt ; NT-probNP ; HF
HFpEF ; New York Heart association ; ejection fraction ; fes
depressed left ventricular ; vn ; systolic pressure ; pressure ; ejection fraction ; cardiac output ; LV ; end-diastolic pressure ; metoprolol
baroreflex Activation Therapy ; Heart Failure ; Reduced ejection Fraction ; carotid ; baroreflex activation therapy ;BAT ; advanced heart failure ;HF
hazard ratio ;HR ;HR
HF ; raised blood glucose levels ; obesiteit ; tobacco ; systemic hypertension ;SH ; rheumatic fever ; chagas ; disease ; la
cRF ; overweight ; obese body mass index
ncwt ; HFpEF ;log rank ; EF
egFR ; egFR ; egFR ; uncontrolled hypertension ; diuretics ; ESRD
myocardial phosphodiesterase-2 ; pde2 ; heart failure ;HF ; pde2-mediated effects ; beta-adrenergic receptor ;Î²-AR ; cardiomyocytes
heart failure ; cardiac resynchronization therapy ; defibrillator ; implantable cardioverter-defibrillator device ; carvedilol ; ATP ; shock therapy ; metoprolol
ERC ; epicatechin-rich cocoa ; Skm ; mitochondrial structure ; taub ; Ramirez-sanchez ; ciaraldi ; perkins ; Murphy ; naviaux ; Hogan ; ceballos ; Maisel ; Henry
follow-up visits ; death ; urgent readmission
mena overexpression ; TTA ; tgtetMena ; TAC surgery ; cardiac hypertrophy ; TTA ; tgtetMena ; cardiac functional
echocardiography ; LV ; end-diastolic volume ; m2 ; MR ; mitral valve ; mva ; mean pressure gradient
PD ; diuretic refractory ; severe-end-stage HF ; PDrelated complications
ATP ; mitochondrial oxidation ; glucose ; lactate ; fatty acids ; myocardial glycolysis
eplerenone ; potassium ; potassium ; hyperkalemia ; medication
New York Heart association ; heart failure ;HF ; ventricular ejection fraction ; permanent periodic breathing ; pb
bottleneck stent ; proximal LAD ; lx ; porcine ; reversible myocardial ischemia ; open stent ; ischemic heart failure ; stent
Potassium ; spironolactone ; AAs ; AAs
obese ;SD ; body mass index ; hFPEF
proangiogenic effects ; b ; VEGF pathway ; adenoviral vector ; decoy ; VEGF receptor ; ad-flk ; adenovirus ; ad-c
surgery ; post- lVAD ; AI ; aortic valve ; leaflet repair ; bioprosthetic ; aortic valve replacement ; functional capacity ; cf lVAD ; AI
exercise-induced pulmonary artery systolic pressure ;PASp ; doppler echocardiography ; right ventricular contractile reserve ; pulmonary hypertension ; right heart failure
medline ;EMBAse ; healstar ; cINAHL ; cochrane Library ; Campbell Collaboration ; Joanna Briggs institute etvidence based practice ; Centre for Reviews and Dissemination ; evidence Based practice Centres
systolic heart failure ; Î²-blocker ; angiotensin converting enzyme inhibitor ; angiotensin-receptor blocker
heart failure ; neuro-hormonal system ; angiotensin converting enzyme inhibitors ;angiotensin receptor blockers ; angiotensin converting enzyme inhibitors intolerance ; beta receptor blockers ; mineralocorticoid receptor
open chest model ; twist ; RS ; RS synchrony ; CS ; ste ; co ;rvpo ; RS synchrony ; CS ; BiVP ; co
pacse ; pasp ; fft-to-PASp ratio ;TAPSe ; pasp ; cox regression ; kaplan-meier analyses ; pvse ; pasp
cPET ; CHF ; exercise ; exercise ; exercise
heart failure ;HF ; mRNA ; voltage-gated cardiac ; na+ channel ; Î±-subunit ; scn5a ; encoding ; endoplasmic reticulum
paediatric heart failure ; myocarditis ; dilated cardiomyopathy ; heart failure ; cellular responses ; heart failure ; anthracycline ; malignant disease
Tools for economische analysis of Patient management Interventions ; Heart Failure ; kosten
natriuretic peptides ;NPs ; b-type NP ; n-terminal pro-b-type NP ; acute heart failure ; Emergency Department ; dp ; acute dyspnea
oxygen consumption ; VO2 ; vco2 slope ; exercise ; oscillatory ventilation ; eOV ; end-tidal co2 ;PETco2 ; cardiopulmonary exercise testing
Denmark ; bisphosphonates ; raloxifene
hypertension ; LV dilatation ; LV dysfunction ; MR ; significant MS ; mitral valve ; systolic ; diastolic tethering ; functional etiology ; MS
tolvaptan ; hyponatremia ; verenigde staten ; japan ; congestive heart failure ; diuretic therapy ; sodium levels ; systolic function
left ventricle ; echocardiographic measurements ; baseline echocardiography ; ct ; follow-up echocardiograms
platelet-activating factor ; pbf ; metabolic enzymes ; heart failure ;HF
acute care surgery ; acs ; owt ; transplantation ; medical therapy ; mt ; intravenous inotropes ; ventricular assist devices ;VADs
HFpEF ; ivabradine ; exercise capacity ; left ventricular ; filling pressure ; exercise ; diastolic mitral flow ; diastolic mitral annular velocity
renin-angiotensin-aldosterone system ;RAas ; hFrEF ; angiotensin-converting enzyme inhibitors ; angiotensin receptor blockers ; aldosterone blockade ; HFpEF
lVET ; tonometric indices
heart rate ; blood pressure ; renal function ; spironolactone ; significant ; RAS blockers ;HR ; Î²-blockers
cardiac performance ; Î²-adrenoceptor blockade ; heart failure ; SR ca(2+)-pump function ; cardiac remodeling ; plasma catecholamines
angiotensin-converting enzyme inhibitors ;angiotensin receptor blockers ; Î²-blockers therapy
SS31 ; congestive heart failure ; phenotypes ; mitochondrial damage ; TAC ; mitochondrial proteome ; mitochondrial ; nonmitochondrial protein changes
myofibrillar ca(2+)-stimulated ATPase activity ; mRNA levels ; SR ca(2+)-pump ; phospholamban ; Î±-myosin heavy chain ; mRNA ; Î²-myosin heavy chain ; metoprolol
HDl ; healthy ;HDl ;healthy ; CHF-NYha-III ;HDl ; nyha-IIIb ; ET ; CHF-NYha-II ;HDl ;NYha-II
anesthetized dogs ; coronary microembolization-induced HF ; cXL-1020 ; left ventricular ; end-diastolic pressure ; myocardial oxygen consumption ; ejection fraction ; ventricular power index
md ; 95% confidence level ; md ; md ; 95% confidence level ; md
heart failure ; t1-mapping ; contrast agent ; contrast agent
HF ; la ; idiopathic dilated cardiomyopathy ; c'd ; ischemic ; SH ; valvular ; alcohol
ST2 ; functional capacity ; ambulatory patients ; HF ; Heart Failure ; Exercise Training ; HF
cardiopulmonary exercise testing ; exercise rehabilitation ; patients met chronic heart failure ; heart failure ; ncw ; Cardiopulmonary Exercise testing ; cmt ; exercise rehabilitation ; europese
AA ; ischemic HF ; wha ; functional class IV ; glomerular filtration rate ; heart rate ; hypertension ; diabetes mellitus ; myocardial infarction
HF-acTION ; exercise training ; HF ; low left ventricular ejection fractions ; HRQol ; Kansas City Cardiomyopathy Questionnaire ; ncwt
ct ; systolic dysfunction ; resynchronization reverses remodeling ; systolic left v entricular dysfunction ; reversie ; left ventricular ; vn ; ejection fraction ; lEF
glomerular filtration rate ; egFR ; diabetes ; total cholesterol ; lDL-cholesterol ; CLcnka gg genotype
echocardiography ; LV ; end-diastolic dimension ; LV ; end-diastolic pressure ;wall stress ; lung weight ; aCF ; sham group
s'lateral ; aUC ; s'lateral ; aUC
spironolactone ; hospitalization ; significante hazard ratio ; death
Rate-control ; cardiac procedures ; cardioversions ; kosten ; antiarrhythmic drugs ;CAD ; confidence interval ; CI
diabetes mellitus ; cardiomyopathy origin ; Î²-blocker ; angiotensin-converting enzyme inhibitor ; angiotensin II receptor blocker
eplerenone ; post myocardial infarction ; Heart failure Efficacy ; survival Study ; eweSUS ; post-myocardial infarction ; heart failure ; mortaliteit ; aldosterone antagonist ; eplerenone
carvedilol ; metoprolol ; implantable ; cardioverter-defibrillator therapy ; MAD-crt ; multicenter Automatic Defibrillator Implantation With Cardiac resynchronization Therapy
HR ; heart failure-related mortaliteit ; sudden death ; HR
DASh ; srd ; brachial systolic pressure ; hg ; centrale end-systolic pressure ; hg
HF ; obese ; body mass index ; black ethnicity ; cardiomyopathy
mortaliteit ;HF ; LVEF ; Heart Failure Survey ; israel
left ventricular ejection fraction ; world Health Organization ; idiopathic dilated cardiomyopathy ; negative coronary angiography
europese Society of Cardiology ; hFPEF ; heart failure ; ejection fraction ; non-dilated left ventricle ; diastolic dysfunction ;impaired LV relaxation ; LV diastolic stiffness ; LV filling pressures
Î²1ARs ; s1PR1s ; myocyte ; cAMP production ; receptors ; regulatory ; g-protein-coupled receptor kinase-2
follow-up ; PAf-cp ; PAf ; lyso-paf-at ; PAf-AH ; lp-PLA2
heart failure ; mean ejection fraction ; cardiac rehabilitation ; Nordic walking ; exercise
ncw-stratified hazard ratios ; sitagliptin ; pioglitazone ; sitagliptin ; sulfonylureas ; sitagliptin ; insulin
skeletal muscle mass ; t-score ; sarcopenic range ; muscle wasting ; t-score ; significant ; t-score
testosterone group ; oxygen uptake ; Beck depression inventory ; leg strength ; Medical Outcomes Study Short-form quality of life domains ; exercise ; placebo group
significante ; all-cause mortaliteit ; HF ; readmissions ; hbf ;hazard ratio ;HR ; confidence interval ; cm
Heart Failure ; controlled trial Investigating Outcomes of Exercise Training ;HF-action ; social support ; barriers to exercise ; social support score ; pss ; barriers to exercise score ; btes
ST2 ; death ; hospitalization ;hazard ratio ; cardiovascular death ; HF ; hospitalization ;hazard ratio ; mortaliteit ;hazard ratio
New York Heart association ; Fontan ; cardiopulmonary exercise ; lean mass quantification ; dual x-ray absorptiometry ; dXA ; calf muscle ; magnetic resonance spectroscopy
placebo ; dopamine ; nesiritide ; diuretic therapy ; renal function ; acute heart failure ; renal dysfunction
cRT ; New York Heart association ; heart failure ; left ventricular ejection fraction ; QRs ; echocardiographic ; left ventricular dyssynchrony
left ventricular ; vn ; ejection fraction ;HF ; right-sided cardiac catheterization ; transthoracic echocardiography ; transmitral flow velocities ; mitral annulus velocities ; systole ; diastole
acute coronary syndromes ; CAD ; bNP ; NT-probNP ; CAD
HF ; lyso-paf-at ; PAf-cp ; PAf ; PAf-AH ; lp-PLA2
sternotomy ; aortic valve ; bioprosthetic valve replacement ; dacron patch closure ; aortic valve ; transcatheter ; aortic valve ; open surgery ; aortic valve replacement
plasma ; n-terminal pro-b-type natriuretic peptide ; n-probNP ; acute heart failure ;HF ; emergency department ; dc
cardiac troponin t ; ctnt ; high-sensitiviteit assay ; n-terminal pro-b-type natriuretic peptide ; n-probNP ; biomarkers ; HF ; HF ; Atherosclerosis Risk in Communities ;ARIc
body mass index ;HR ; fat mass ; fat-free mass index
interquartile range ; body mass index ; interquartile range ; COPd ; CHF ; cRF
reverse remodeling ; ejection fraction ; mortaliteit ; all-cause hospitalizations ;HF ; dialysis patients
eh ; LV contractility ; CH ; LVEF ; systolic blood pressure ; end-systolic volume ;Î² coefficient ; hg
echocardiography ; LV ; end-diastolic volume index ; ml ; m2 ; LV ; ejection fraction ; MR ; mitral valve opening ; significant MS ; mva ; mean pressure gradient ; hg
acute heart failure ; renal dysfunction ; glomerular filtration rate ;ROSe
molecular analysis ; bets ; chromatin-mediated signal transduction ; Pol II ; co-activating transcription factor ; HF pathogenesis ; nuclear factor of activated t cells ; nFAT ; nuclear factor-Îºb ;NF-Îºb ; transcription factor ; gATA4
mortaliteit ; hospitalization ; exercise tolerance ; cardiovascular events ; myocardial infarction ; congestive heart failure exacerbation ; arrhythmia ; cardiac death ; hypertension ; venous thromboembolic events ; ischemic cerebrovascular events
cardiovascular mortaliteit ; hazard ratio
EO-cFUs ; diabetes ; diabetes ;EO-cFU ; VO2 ; diabetes ; EO-cFUs ; VO2
immunoblotting ; radioenzymatic- ; fluorescence resonance ; energy transfer-based assays ; video edge detection ; epifluorescence microscopy ; l-type ca2 ; myocardial tissues ; cardiomyocytes ; hb
east ; Atrial fibrillation ; Stroke prevention trial ; AF ; stroke ;cha2d2VASc ; early rhythm control therapy
Exercise capacity ; oxygen consumption ; v2 ; QOL ; Minnesota Living with Heart Failure ; mwt ; Questionnaire ; heart failure-related QOL
proteomic ; mitochondrial-targeted peptide ; SS31 ; mitochondrial function ; upstream signal ; TAC ; mitochondrial-targeted peptide ; drugs ; heart failure
low left ventricular ejection fraction ;HF ; left ventricular ejection fraction ; hospital ; physicians ; inpatient settings ; financiÃ«le kosten
HF ;HFrEF ; left ventricular ; vn ; ejection fraction ;HFpEF ; echo-doppler studies ; pro-brain-type natriuretic peptide assessment
low-volume EDs ; hospitalized ; aOR ; high-volume EDs ; aOR
cardiac transplant ; ect ; diabetes mellitus ; chronic kidney disease ; glomerular filtration rate
hbc Battery scores ; Health ABC ;HF Risk model ; discrimination ; c-index ; HF
cfi ; RMsea ; Self-care Maintenance Scale ; cfi ; RMsea ; Self-care management Scale ; cfi ; Self-care Confidence scale
BAT ; quality-of-life score ; wha ; functional class ranking
hypoalbuminemia ; postoperative ; albumin levels ; hypoalbuminemia ; albumin levels ; lVAD
rehospitalization ; cm ; acute myocardial infarction ;AMI ; kidney infection ; urinary tract infection ;UTI
heart failure ;HF ; ischemic ; nonischemic cardiomyopathies ; pharmacological armamentarium ; implantable cardioverter defibrillators ; cardiac resynchronization therapy ; cardiac transplantation ; left ; right ventricular assist devices
SAF ; PF ; catheterization ; centrale venous pressure ; hg ; rv index ; dyn ; cardiac index
admission median bNP ; EF ; EF ; median bNP ; EF ; borderline
heart failure ; heart transplantation ;LV assist device ; death ;hazard ratio ; all-cause death
LV ; ejection fraction ; circumferential shortening ; systolic elastance ; contractile efficiency ; aCF ; aCF ; allopurinol rats ; o2 consumption rate ; isolated cardiomyocytes ; extracellular flux analyzer
HFpEF ; LV ; geometry ; LV hypertrophy ;LVh ; relative wall thickness ; rwt ; CR ; LVh ; rwt ; eh ; vwt
lCZ696 ; angiotensin receptor ; neprilysin inhibitor ; neprilysin inhibitor ; prodrug ; angiotensin receptor antagonist valsartan ; hypertension ; heart failure ; preserved ejection fraction ; heart failure ; reduced ejection fraction
blood pressure ; hg ; mitral valve ; degenerative MR ; p3 prolapse ; chordal ruptures ; triangular resection ; edge-to-edge anastomosis ; ring annuloplasty ; Physio ring 30 ;Edwards Lifesciences ; irvine ; CA
shuttle walk test ; oxygen uptake ; muscular strength ; echocardiographic ; natriuretic peptide ; inflammatory markers ; depression ; beck depression inventory ;Minesota Living with Heart Failure Questionnaire ; Medical
LVEF ; hm ; mortaliteit ; LVEF ; h
westar-Kyoto ; lean ; ncwt ; obese ; ncwt ; obese ; ncwt ; high-fat diet ; metabolic ; renal ; echocardiographic ; hemodynamically ; euthanization
kaplan-meier curves ; log-rank testing ; UM
multivariate cox regression analyses ; AF ; AF ; hypertension ; sinus rhythm ;hazard ratio ;HR ; confidence interval ; cm
chronic HF-ref ; NYha ; functional class II ; egFR ; potassium ; eplerenone ; hyperkalemia ; wRF
fm ; FM ; body fat ; dual energy ; X-ray absorptiometry ; dXA ; non-diabetic patients ; chronic heart failure ; ncw ;cc ; non-cachectic CHF ; myocardial infarction-both
spironolactone ; end point ; hospitalization ; HF ;hazard ratio ; AAs ;hazard ratio
invasively diagnose ; pulmonary arterial hypertension ; inoperable chronic thromboembolic pulmonary hypertension ; right ventricular pump ; pulmonary arterial hypertension ; medication ; stress echocardiography ; cardiopulmonary exercise testing
cardiovascular death ; HF hospitalization ; significant ; btes ; btes ; cardiovascular death ; HF ; hospitalization ; exercise group ;hazard ratio
CAD ; diabetes ;odds ratio ; electrocardiographic Q waves ; left bundle branch block ;odds ratio ; nondiabetes risk factors ; dyslipidemia ; hypertension ; tobacco use ;odds ratio
index ED visit ; low-volume ED cases ; death ; all-cause readmission ; medium ; aOR ; high-volume EDs ; aOR
implantable cardioverter-defibrillator deactivation ; implantation ; significant ; implantable cardioverter-defibrillator deactivation
Cardiac magnetic resonance ;hazard ratio ; left atrial area ;hazard ratio ; pulmonary vascular resistance ;hazard ratio ; cardiac events
HF ; systolic ; left ventricular ejection fraction ; HF ; New York Heart association ; echocardiographic ; cardiopulmonary exercise test
heart failure ; abd ; American college of Cardiology ; acc ;American Heart association ;AHA ; New York Heart association ; wha ; structural heart disease ; heart failure ; physical exertion ; medical
mva ; continuiteit equation ; vn ; end-diastolic volume ; LV ; end-systolic volume ; mitral filling flow ; mva ; velocity time ; mitral filling flow ; continuous wave ; doppler echocardiography ; MR ; mitral valve plasty
RM ; mortaliteit ; sts HH ;HR ; cri ; mt ; office hours ;HR ; Cri
HFPSI ; Ann arbor Veterans' Affairs ; HF clinic ; va cohort ; HFPSI ; va-RT cohort ; va patients ; HFPSI
hFrEF ; diuretics ; co-morbidities ; mwt ; nyha class III
HF ; echocardiography ; LV ; end-diastolic volume index ; LV ; ejection fraction ; MR ; mitral valve opening ; mitral valve area ; mva ; mean pressure gradient ; hg
AAs ; spironolactone dose ; hyperkalemia ;potassium ; hypokalemia ;potassium
LVEF ; long-term mortaliteit ; LVEF ;hazard ratio ;HR ; LVEF ; preserved LVEF ;HR
HFpEF ; male gender ;odds ratio ; nyha class III ; walk test ; mwt
pulmonary arterial systolic pressure ;PASp ; right ventricular ; vn ; tricuspid annular plane systolic excursion ;TAPSe ; diastole ; end-systole ; heart failure ;HF ; cardiac risk
LV ; reverse remodeling ; LV ; end-diastolic dimension index ; left ventricle ; left atrial area ; right ventricular ; end-diastolic area index ; right atrial area ; right ventricular fractional area
receiver ; operating characteristic curve ; abc ; pcw ; confidence interval ; e/e ;septal ; ewean
iRS1 ; iRS2 ; heart ; hyperinsulinemia ; myocardial insulin resistance ; cellular dysfunction ; iRS2 ; heart-specific ; iRS1 ; iRS2 ; double-knockout ; l-dko
b-type natriuretic peptide ; n-terminal pro-b-type natriuretic peptide ; coronary artery disease ; b-type natriuretic peptide ; bn ; n-terminal fragment ; nc-probp ; ventricular cardiomyocytes ; ventricular wall stress ; myocardial ischemia
trastuzumab-treated patients ; HR ; coronary artery disease ;HR ; hypertension ;HR ; trastuzumab administration ;HR ; CHF
LVEF ; composite response ; cRT on ; cRT OFF ; LV ; systolic volume index ; LV mass
tbf-Î² signaling ; tGF-Î² receptor type I ; smad ; small-molecule inhibitors ; c-Kit+ cell yield ; epithelial ; mesenchymal transition markers ; pluripotency marker ; nanog ; c-Kit+ cell ; cardiomyocyte-like cells
systolic heart failure ;ejection fraction ; ivabradine ; SHIft ; systolic Heart failure ; Treatment ; If inhibitor ivabradine trial ; ivabradine ; echocardiographic
liberal transfusion ; mortaliteit ; i2 ; mortaliteit ; acute coronary syndrome
death ; unplanned readmission ; familiar physician ; evaluated hazard ratio ;HR ; confidence interval ; cm ; early follow-up visits ; follow-up visits
Hazard ratios ; pb ;hazard ratio ;HR ; pb ; ncw Heart association ; functional class ;HR
hek ;human embryonic kidney ; Î²1ar ; s1PR1 ; Î²1ar ; downregulation ; sphingosine-1-phosphate ; s1PR1 ; agonist ; isoproterenol ; Î²-adrenergic receptor agonist
walked ; kansas City ; cardsiomyopathy Questionnaire ; Minnesota ; Living with Heart Failure Questionnaire ; depressive symptoms ; beck depression inventory ; depression scores ; natriuretic peptide ; endothelial function ;flow-mediated dilatation ; left ventricular diastolic function
Renal function ; Chronic Kidney Disease Epidemiology Collaboration equation ; glomerular filtration rate ; gbf ; mL ; mL
paradigm-HF ; chronic heart failure ; systolic dysfunction ; vn EF ; functional class ; nyha i-III ; bnp ; ncw ; cardiovascular death ; hospitalization ; heart failure ; arni ; lz696 ; sacubiltril ; valsartan
hyperkalemia ; African Americans ; AAs ; non-AAs ; white ; New York Heart association ;NYha ; class III ; wh ; left ventricular dysfunction ; spironolactone ; aldactone evaluation Study ;RALes
cardiovascular events ; atrial fibrillation ; left ventricular ejection fraction ; diabetes mellitus ; peripheral vascular disease ; myocardial infarction ; heart failure ; stroke ; glomerular filtration rate ; acute kidney injury
diastolic function ; Ea ; ventricular-arterial coupling ; ea
disease risk score ; dRS ; saxagliptin ; sitagliptin ; ci ; saxagliptin ; pioglitazone ; saxagliptin ; sulfonylureas ; saxagliptin ; insulin
IE ; revascularization ; coronary artery bypass ; surgery ;HR ; percutaneous coronary intervention ; HR ; systolic blood pressure ;HR ; left bundle branch block pattern ; baseline electrocardiogram ; h
biomedical treatment ; biomedical treatment ; CHm ; significant ; left ventricular ejection fraction ; left ventricular diastolic end
open-label crossover ; masked outcome assessments ; heart failure ; ventricular ejection fraction ; arg16 ; gtln27 ; haplotype ; Î²2-receptor ; carvedilol ; metoprolol
angiotensin-converting enzyme inhibitors ;angiotensin receptor blockers ; interquartile range ; Î²-blockers ; interquartile range
Therapy ; ivabradine ; diastolic mitral flow velocity ; diastolic mitral annular velocity ; exercise capacity ; ivabradine ; oxygen uptake
PAf ; biosynthetic enzymes ;lyso-paf ; acetyltransferase ;lyso-paf-at ; dithiothreitol ; dt ; sensitive ; cdp ; choline ; 1-alkyl-2-acetyl-sn-glycerol ; cholinephosphotransferase ; pbf-cp ; catabolic isoenzymes ; paf-acetylhydrolase ; pbf-AH ; lipoprotein-associated phospholipase a2 ; lp-PLA2] ; leukocytes
low-volume ED cases ; death ;hospitalization ;ED visit ; aOR ; aOR ; high-volume ED cases ; aOR
ivabradine group ; follow-up ; exercise capacity ; oxygen uptake ; early diastolic mitral flow velocity ; diastolic mitral annular velocity
Health Buddy Program ; mortaliteit ;hazard ratio ;HR ; confidence interval ;CI ; inpatient admissions
multivariable-adjusted hazard ratios ; DASh ; diet score
ctnt ; NT-probNP ;laboratory report ; aRIC HF ; systolic blood pressure ; antihypertensive medication ; smoking ; diabetes ; body mass index ; coronary heart disease ; heart rate ; HF ; receiver ; operating characteristic curve ; abc ; discrimination improvement ; net reclassification improvement ; nRI
eplerenone ; hyperkalemia ; renal function ; wRF ; EMPHASIS-HF ; heart failure ; ejection fraction ;HF-ref ; New York Heart association ; nyha ; functional class II ; glomerular filtration rate ; egFR ; serum potassium
follow-up ; NYha classification ; class II ; patients ; class I ; Duke Activiteit Status index ; Kansas City Cardiomyopathy Questionnaire ; walk test distance ;SD
placebo ; low-dose dopamine ; significant ; urine volume ;dopamine ; placebo ; mL ; cystatin c level ;dopamine ; placebo
low-dose nesiritide ; urine volume ;nesiritide ; placebo ; mL ; cystatin c level ;nesiritide ; placebo
Nordic walking ; functional capacity ; mwt ; physical activity ; right grip strength ; depressive symptoms ;Hospital anxiety ; depression Scale
hyperkalemia ; wRF ; diabetes ; egFR ; systolic blood pressure ; hg ;potassium ; hyperkalemia ; wRF ;hospitalization ; HF ; cardiovascular mortaliteit
hazard ratio ;HR ; ncw ; baseline glomerular filtration rate ;HR ; chronic obstructive pulmonary disease ;HR ; diabetes ;HR ; peripheral vascular disease ;HR ; left ventricular ejection fraction ; h ; iCD shocks ; h ; New York Heart association ; atrial fibrillation ; congestive HF ; mortaliteit
oxygen uptake ; hazard ratio ;HR ; confidence interval ; ventilatory efficiency slope ; hemoglobin ; left ventricular ejection fraction ; renal function ; renal disease ; sodium
Kansas City ; Cardiomyopathy Questionnaire ; Minnesota ; Living with Heart Failure Questionnaire ; Beck depression inventory ; zweng ; flow-mediated dilatation diameter ; fes ; placebo ; b-type natriuretic peptide ; mitral ; wave ratio
CHF ;Odds Ratio ; ht ; chest radiation ; hypertension ; genes coding ; NAD-h-oxidase subunit RAC2 ; hbf ; doxorubicin efflux transporter ; abc2
